<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>CVS Group plc (OTCPK:CVSGF) Q4 2025 Earnings Call October 7, 2025 4:00 AM EDT<br><br>Company Participants<br><br>Richard William Fairman - CEO & Director<br>Robin Alfonso - CFO & Director<br>Paul Higgs - Chief Veterinary Officer<br><br>Conference Call Participants<br><br>Charles Hall - Peel Hunt LLP, Research Division<br>Kane Slutzkin - Deutsche Bank AG, Research Division<br>Andrew Whitney - Investec Bank plc, Research Division<br>James Bayliss - Joh. Berenberg, Gossler & Co. KG, Research Division<br>Charles Weston - RBC Capital Markets, Research Division<br>Sahill Shan - Singer Capital Markets Securities Limited, Research Division<br><br>Presentation<br><br>Richard William Fairman<br>CEO & Director<br><br>All right.</td><td>CVS Group plc (OTCPK:CVSGF) 2025ë…„ 4ë¶„ê¸° ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2025ë…„ 10ì›” 7ì¼ ì˜¤ì „ 4:00 EDT<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>Richard William Fairman - CEO ê²¸ ì´ì‚¬<br>Robin Alfonso - CFO ê²¸ ì´ì‚¬  <br>Paul Higgs - ìµœê³ ìˆ˜ì˜ì‚¬<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>Charles Hall - Peel Hunt LLP, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Kane Slutzkin - Deutsche Bank AG, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Andrew Whitney - Investec Bank plc, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>James Bayliss - Joh. Berenberg, Gossler & Co. KG, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Charles Weston - RBC Capital Markets, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Sahill Shan - Singer Capital Markets Securities Limited, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>Richard William Fairman<br>CEO ê²¸ ì´ì‚¬<br><br>ì¢‹ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Good morning, everyone, and welcome to this live stream of CVS Group's full year financial results following the publication of those earlier this morning. I'm Richard Fairman, CEO. And alongside me, I've got Robin Alfonso, our CFO; and Paul Higgs, our Chief Veterinary Officer. We have delivered further growth across our group in the past year with improved U.K. operations and continuing expansion of our platform in Australia. Revenue increased by 5.4% to GBP 673.2 million.</td><td>ì•ˆë…•í•˜ì„¸ìš” ì—¬ëŸ¬ë¶„, CVS Groupì˜ ì—°ê°„ ì¬ë¬´ ì‹¤ì  ë¼ì´ë¸Œ ìŠ¤íŠ¸ë¦¼ì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì•„ì¹¨ ì¼ì° ë°œí‘œëœ ì‹¤ì ì„ ë°”íƒ•ìœ¼ë¡œ ì§„í–‰í•˜ê² ìŠµë‹ˆë‹¤. ì €ëŠ” CEO ë¦¬ì²˜ë“œ í˜ì–´ë§¨ì…ë‹ˆë‹¤. ì œ ì˜†ì—ëŠ” CFO ë¡œë¹ˆ ì•Œí°ì†Œì™€ ìµœê³ ìˆ˜ì˜ì‚¬ í´ í‰ìŠ¤ê°€ í•¨ê»˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì§€ë‚œ í•œ í•´ ë™ì•ˆ ì˜êµ­ ì‚¬ì—…ë¶€ì˜ ê°œì„ ê³¼ í˜¸ì£¼ í”Œë«í¼ì˜ ì§€ì†ì ì¸ í™•ì¥ì„ í†µí•´ ê·¸ë£¹ ì „ë°˜ì— ê±¸ì³ ì¶”ê°€ì ì¸ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë§¤ì¶œì€ 5.4% ì¦ê°€í•œ 6ì–µ 7,320ë§Œ íŒŒìš´ë“œë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We faced some challenges particularly in the first half of the year with softer market conditions in the U.K., but it was pleasing to see significant improvement in the final quarter, leading to a positive full year performance with like-for-like growth of 0.2% across the group and 1% in our core practice division. And then improved trading continued into the first quarter of the new financial year. Adjusted EBITDA increased by 9.4% to GBP 134.6 million from both acquisitions and continued disciplined cost management, and adjusted EBITDA margin increased by 70 basis points to 20%. Adjusted operating cash conversion was 76.9% for the year, ahead of our stated ambition of circa 70%.</td><td>íŠ¹íˆ ì—°ì´ˆ ìƒë°˜ê¸°ì—ëŠ” ì˜êµ­ì˜ ì‹œì¥ ì—¬ê±´ ë‘”í™”ë¡œ ì¼ë¶€ ì–´ë ¤ì›€ì„ ê²ªì—ˆì§€ë§Œ, 4ë¶„ê¸°ì— ìƒë‹¹í•œ ê°œì„ ì„¸ë¥¼ ë³´ì¸ ê²ƒì€ ê³ ë¬´ì ì´ì—ˆìœ¼ë©°, ì´ë¡œ ì¸í•´ ê·¸ë£¹ ì „ì²´ ê¸°ì¤€ ë™ì¼ë§¤ì¥ ì„±ì¥ë¥  0.2%, í•µì‹¬ ì§„ë£Œ ë¶€ë¬¸ 1%ì˜ ê¸ì •ì ì¸ ì—°ê°„ ì‹¤ì ì„ ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ê°œì„ ëœ ê±°ë˜ íë¦„ì€ ì‹  íšŒê³„ì—°ë„ 1ë¶„ê¸°ê¹Œì§€ ì§€ì†ë˜ì—ˆìŠµë‹ˆë‹¤. ì¡°ì • EBITDAëŠ” ì¸ìˆ˜í•©ë³‘ê³¼ ì§€ì†ì ì¸ ì—„ê²©í•œ ë¹„ìš© ê´€ë¦¬ë¥¼ í†µí•´ 9.4% ì¦ê°€í•œ 1ì–µ 3,460ë§Œ íŒŒìš´ë“œë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì¡°ì • EBITDA ë§ˆì§„ì€ 70bp ì¦ê°€í•œ 20%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì¡°ì • ì˜ì—…í˜„ê¸ˆì „í™˜ìœ¨ì€ ì—°ê°„ 76.9%ë¡œ ë‹¹ì‚¬ê°€ ëª©í‘œë¡œ í–ˆë˜ ì•½ 70% ìˆ˜ì¤€ì„ ìƒíšŒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And in light of these strengthened operating cash flows and also the proceeds from the sale of our Crematoria business at a 10x EBITDA multiple, we finished the year with leverage of 1.18x. We completed a further 7 practice acquisitions in Australia, and we've completed a further 2 acquisitions comprising 8 practice sites so far this new financial year. And that brings our total footprint in Australia to 51 sites. We're coming towards the end of the CMA market investigation. And whilst it was disappointing to face a further delay in the announcement of their provisional decision, we do look forward to receiving that very shortly.</td><td>ì´ëŸ¬í•œ ê°•í™”ëœ ì˜ì—…í˜„ê¸ˆíë¦„ê³¼ ë”ë¶ˆì–´ í™”ì¥ì¥ ì‚¬ì—…ì„ EBITDA 10ë°° ë°°ìˆ˜ë¡œ ë§¤ê°í•œ ìˆ˜ìµê¸ˆì„ í†µí•´ ì—°ë§ ë ˆë²„ë¦¬ì§€ ë¹„ìœ¨ì„ 1.18ë°°ë¡œ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. í˜¸ì£¼ì—ì„œ 7ê°œì˜ ì¶”ê°€ ë³‘ì› ì¸ìˆ˜ë¥¼ ì™„ë£Œí–ˆìœ¼ë©°, ì‹ íšŒê³„ì—°ë„ ë“¤ì–´ í˜„ì¬ê¹Œì§€ 8ê°œ ë³‘ì› ì‚¬ì´íŠ¸ë¡œ êµ¬ì„±ëœ 2ê±´ì˜ ì¶”ê°€ ì¸ìˆ˜ë¥¼ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. ì´ë¡œì¨ í˜¸ì£¼ ë‚´ ì´ ì‚¬ì—…ì¥ ê·œëª¨ëŠ” 51ê°œ ì‚¬ì´íŠ¸ê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. CMA ì‹œì¥ì¡°ì‚¬ê°€ ê±°ì˜ ë§ˆë¬´ë¦¬ ë‹¨ê³„ì— ì™€ ìˆìŠµë‹ˆë‹¤. ì ì • ê²°ì • ë°œí‘œê°€ ì¶”ê°€ë¡œ ì§€ì—°ëœ ê²ƒì€ ì‹¤ë§ìŠ¤ëŸ½ì§€ë§Œ, ì¡°ë§Œê°„ ê·¸ ê²°ê³¼ë¥¼ ë°›ì•„ë³¼ ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Now the strong market fundamentals remain attractive and we are well positioned for further growth. We've strengthened our company, and we're confident with the future growth prospects. So with that, I'd now like to open the call to questions from analysts. Now given this call is being live streamed, when you ask a question, please state your name and firm. And I think that will be helpful.</td><td>ì´ì œ ê²¬ê³ í•œ ì‹œì¥ í€ë”ë©˜í„¸ì´ ì—¬ì „íˆ ë§¤ë ¥ì ìœ¼ë¡œ ë‚¨ì•„ìˆìœ¼ë©°, ì €í¬ëŠ” ì¶”ê°€ ì„±ì¥ì„ ìœ„í•œ ì¢‹ì€ í¬ì§€ì…˜ì— ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” íšŒì‚¬ë¥¼ ê°•í™”í–ˆê³ , ë¯¸ë˜ ì„±ì¥ ì „ë§ì— ëŒ€í•´ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ ì• ë„ë¦¬ìŠ¤íŠ¸ ë¶„ë“¤ì˜ ì§ˆë¬¸ì„ ë°›ëŠ” ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ ì½œì´ ì‹¤ì‹œê°„ìœ¼ë¡œ ìŠ¤íŠ¸ë¦¬ë°ë˜ê³  ìˆìœ¼ë‹ˆ, ì§ˆë¬¸í•˜ì‹¤ ë•Œ ì„±í•¨ê³¼ ì†Œì† íšŒì‚¬ëª…ì„ ë§ì”€í•´ ì£¼ì‹œë©´ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">â€¢ ì£¼ìš” ì¬ë¬´ì„±ê³¼:<br>- ë§¤ì¶œ 5.4% ì¦ê°€í•˜ì—¬ Â£673.2M ê¸°ë¡<br>- ì¡°ì • EBITDA 9.4% ì¦ê°€í•˜ì—¬ Â£134.6M ë‹¬ì„± (ë§ˆì§„ 20%, 70bp ìƒìŠ¹)<br>- ì˜ì—…í˜„ê¸ˆì „í™˜ìœ¨ 76.9% ë‹¬ì„± (ëª©í‘œ 70% ìƒíšŒ)<br>- ë¶€ì±„ë¹„ìœ¨ 1.18xë¡œ ê°ì†Œ<br><br>â€¢ ì‚¬ì—… í˜„í™©:<br>- ì˜êµ­ ì‹œì¥ ìƒë°˜ê¸° ë¶€ì§„í–ˆìœ¼ë‚˜ 4ë¶„ê¸° ì‹¤ì  ê°œì„ ë˜ë©° ì—°ê°„ ë™ì¼ë§¤ì¥ ì„±ì¥ë¥  0.2% ê¸°ë¡<br>- í˜¸ì£¼ ì‚¬ì—… í™•ì¥ ì§€ì† (7ê°œ ë³‘ì› ì¸ìˆ˜, í˜„ì¬ ì´ 51ê°œ ì§€ì  ìš´ì˜)<br><br>â€¢ ì „ë§:<br>- ì‹ ë…„ë„ 1ë¶„ê¸° ì‹¤ì  ê°œì„ ì„¸ ì§€ì†<br>- CMA ì‹œì¥ì¡°ì‚¬ ê²°ê³¼ ì§€ì—°ë˜ì—ˆìœ¼ë‚˜ ê³§ ë°œí‘œ ì˜ˆì •<br>- ê²½ì˜ì§„, ì‹œì¥ í€ë”ë©˜í„¸ê³¼ ì„±ì¥ ì „ë§ì— ëŒ€í•´ ê¸ì •ì  ì…ì¥ í‘œëª…</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Charles Hall: Peel Hunt LLP, Research Division Charles Hall from Peel Hunt. Richard, could we start on Australia? And can you just give a feel for how the market is trending there, now you've got plenty that have been under your belt for every year? Also discuss the synergies you're starting to see and a little bit on the cost of acquisitions and the pipeline.</td><td>**Charles Hall:** Peel Huntì˜ Charles Hallì…ë‹ˆë‹¤. Richard, í˜¸ì£¼ë¶€í„° ì‹œì‘í•´ë³¼ê¹Œìš”? ì´ì œ 1ë…„ ë™ì•ˆ ì¶©ë¶„í•œ ê²½í—˜ì„ ìŒ“ìœ¼ì…¨ëŠ”ë°, ê·¸ê³³ ì‹œì¥ì´ ì–´ë–¤ ì¶”ì„¸ë¥¼ ë³´ì´ê³  ìˆëŠ”ì§€ ê°ì„ ì¢€ ì•Œë ¤ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ë˜í•œ ì‹œë„ˆì§€ íš¨ê³¼ê°€ ë‚˜íƒ€ë‚˜ê¸° ì‹œì‘í•˜ëŠ” ë¶€ë¶„ë“¤ê³¼ ì¸ìˆ˜ ë¹„ìš©, ê·¸ë¦¬ê³  íŒŒì´í”„ë¼ì¸ì— ëŒ€í•´ì„œë„ ë§ì”€í•´ ì£¼ì„¸ìš”.</td></tr>
<tr><td>CEO & Director: Yes. So if I start with the overall performance in Australia. We've been quite selective, as you know, in terms of the acquisitions we've made. We're looking for high-quality, typically larger practices with 4 or 5 vets or more. And we're buying practices consciously in areas of high population and, therefore, areas where there are lots of pets. They also happen to be the areas where vets want to work and live. So that disciplined approach has served as well. We're pleased with the performance in Australia, and we've seen continued growth and the practices are performing in line with business cases. In terms of the market, demand has been good. The margins of those practices are above our group margin. And in terms of investments and financial returns, I'll probably pass over to Robin to comment.</td><td>**CEO & Director:** ë„¤, í˜¸ì£¼ì˜ ì „ë°˜ì ì¸ ì„±ê³¼ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” ì¸ìˆ˜ ê³¼ì •ì—ì„œ ìƒë‹¹íˆ ì„ ë³„ì ìœ¼ë¡œ ì ‘ê·¼í•´ì™”ìŠµë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œ ìˆ˜ì˜ì‚¬ê°€ 4-5ëª… ì´ìƒì¸ ê³ í’ˆì§ˆì˜ ëŒ€í˜• ë³‘ì›ë“¤ì„ ì°¾ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¸êµ¬ ë°€ë„ê°€ ë†’ì€ ì§€ì—­, ì¦‰ ë°˜ë ¤ë™ë¬¼ì´ ë§ì€ ì§€ì—­ì˜ ë³‘ì›ë“¤ì„ ì˜ì‹ì ìœ¼ë¡œ ì¸ìˆ˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ° ì§€ì—­ë“¤ì€ ìˆ˜ì˜ì‚¬ë“¤ì´ ì¼í•˜ê³  ì‚´ê³  ì‹¶ì–´í•˜ëŠ” ê³³ì´ê¸°ë„ í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì²´ê³„ì ì¸ ì ‘ê·¼ ë°©ì‹ì´ ì¢‹ì€ ê²°ê³¼ë¥¼ ê°€ì ¸ë‹¤ì£¼ì—ˆìŠµë‹ˆë‹¤.<br><br>í˜¸ì£¼ì—ì„œì˜ ì„±ê³¼ì— ë§Œì¡±í•˜ê³  ìˆìœ¼ë©°, ì§€ì†ì ì¸ ì„±ì¥ì„ ë³´ì´ê³  ìˆê³  ë³‘ì›ë“¤ì´ ì‚¬ì—… ê³„íšì— ë§ì¶° ì˜ ìš´ì˜ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹œì¥ ì¸¡ë©´ì—ì„œëŠ” ìˆ˜ìš”ê°€ ì–‘í˜¸í–ˆìŠµë‹ˆë‹¤. ì´ë“¤ ë³‘ì›ì˜ ë§ˆì§„ì€ ì €í¬ ê·¸ë£¹ ë§ˆì§„ì„ ìƒíšŒí•˜ê³  ìˆìŠµë‹ˆë‹¤. íˆ¬ìì™€ ì¬ë¬´ ìˆ˜ìµë¥ ì— ê´€í•´ì„œëŠ” ë¡œë¹ˆì´ ë‹µë³€í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CFO & Director: Yes. So I think in terms of -- you asked a couple of questions around kind of cost of acquisition and pipeline. So our cost of acquisition largely are in two buckets. There's the cost of the DD and also Australia has stamp duty. But also in Australia, typically, when we value a business, I think we've said this before, 80% is paid upfront and then a proportion of 20% is deferred over a period of time. That gives us some protection but also leaves the vendor with some skin in the game and the opportunity to earn further value. There are -- that is a contingent consideration and that gets booked as a cost of acquisition through the P&L. In terms of pipeline, the pipeline is strong. I think in Australia, there are probably three major players. There's Greencross, there's VetPartners -- different from VetPartners in the U.K. and ourselves. And together, we have about 15% to 20% of the overall market compared to 60% in the U.K. So there's good opportunity. We spent just under GBP 30 million last year. To date, in the first quarter, we spent about GBP 23 million on two acquisitions, one larger acquisition of 6 sites. And we have a strong pipeline of opportunities where we've got agreed terms, we're just running through DD, and a much longer list of opportunities of people that we're talking to. So there's a really good strong opportunity for further growth in Australia.</td><td>**CFO & Director:** ë„¤, ì¸ìˆ˜ ë¹„ìš©ê³¼ íŒŒì´í”„ë¼ì¸ì— ëŒ€í•œ ëª‡ ê°€ì§€ ì§ˆë¬¸ì„ ì£¼ì…¨ëŠ”ë°ìš”. ì €í¬ ì¸ìˆ˜ ë¹„ìš©ì€ í¬ê²Œ ë‘ ê°€ì§€ ë²”ì£¼ë¡œ ë‚˜ë‰©ë‹ˆë‹¤. ì‹¤ì‚¬(DD) ë¹„ìš©ì´ ìˆê³ , í˜¸ì£¼ì—ëŠ” ì¸ì§€ì„¸ë„ ìˆìŠµë‹ˆë‹¤. ë˜í•œ í˜¸ì£¼ì—ì„œëŠ” ì¼ë°˜ì ìœ¼ë¡œ ì‚¬ì—…ì„ í‰ê°€í•  ë•Œ - ì´ì „ì—ë„ ë§ì”€ë“œë¦° ë°” ìˆì§€ë§Œ - 80%ëŠ” ì„ ë¶ˆë¡œ ì§€ê¸‰í•˜ê³  ë‚˜ë¨¸ì§€ 20%ëŠ” ì¼ì • ê¸°ê°„ì— ê±¸ì³ ì´ì—° ì§€ê¸‰í•©ë‹ˆë‹¤. ì´ëŠ” ì €í¬ì—ê²Œ ì–´ëŠ ì •ë„ ë³´í˜¸ë§‰ì„ ì œê³µí•˜ë©´ì„œë„ ë§¤ë„ìê°€ ê³„ì† ê´€ì‹¬ì„ ê°–ê³  ì¶”ê°€ ê°€ì¹˜ë¥¼ ì°½ì¶œí•  ê¸°íšŒë¥¼ ë‚¨ê²¨ë‘¡ë‹ˆë‹¤. ì´ëŠ” ì¡°ê±´ë¶€ ëŒ€ê°€(contingent consideration)ì´ë©° ì†ìµê³„ì‚°ì„œë¥¼ í†µí•´ ì¸ìˆ˜ ë¹„ìš©ìœ¼ë¡œ ê³„ìƒë©ë‹ˆë‹¤. <br><br>íŒŒì´í”„ë¼ì¸ ì¸¡ë©´ì—ì„œëŠ” ìƒë‹¹íˆ ê²¬ê³ í•©ë‹ˆë‹¤. í˜¸ì£¼ì—ëŠ” ì•„ë§ˆ 3ê°œì˜ ì£¼ìš” ì—…ì²´ê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. í˜¸ì£¼ì—ëŠ” Greencrossê°€ ìˆê³ , VetPartnersê°€ ìˆìŠµë‹ˆë‹¤ - ì˜êµ­ì˜ VetPartnersì™€ëŠ” ë‹¤ë¥¸ íšŒì‚¬ì´ê³ , ì €í¬ë„ ìˆìŠµë‹ˆë‹¤. ì´ ì„¸ íšŒì‚¬ë¥¼ í•©ì³ì„œ ì „ì²´ ì‹œì¥ì˜ ì•½ 15%ì—ì„œ 20% ì •ë„ë¥¼ ì°¨ì§€í•˜ê³  ìˆëŠ”ë°, ì´ëŠ” ì˜êµ­ì˜ 60%ì™€ ë¹„êµí•˜ë©´ ìƒë‹¹í•œ ì°¨ì´ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì¢‹ì€ ê¸°íšŒê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤.<br><br>ì‘ë…„ì— 3ì²œë§Œ íŒŒìš´ë“œ ì¡°ê¸ˆ ì•ˆ ë˜ëŠ” ê¸ˆì•¡ì„ íˆ¬ìí–ˆìŠµë‹ˆë‹¤. ì˜¬í•´ 1ë¶„ê¸° í˜„ì¬ê¹Œì§€ëŠ” ë‘ ê±´ì˜ ì¸ìˆ˜ì— ì•½ 2ì²œ3ë°±ë§Œ íŒŒìš´ë“œë¥¼ íˆ¬ìí–ˆëŠ”ë°, ê·¸ ì¤‘ í•˜ë‚˜ëŠ” 6ê°œ ì‚¬ì´íŠ¸ë¥¼ ë³´ìœ í•œ ê·œëª¨ê°€ í° ì¸ìˆ˜ì˜€ìŠµë‹ˆë‹¤. <br><br>í˜„ì¬ ì¡°ê±´ í•©ì˜ê°€ ì™„ë£Œë˜ì–´ ì‹¤ì‚¬(DD) ê³¼ì •ì„ ì§„í–‰ ì¤‘ì¸ ê°•ë ¥í•œ ê¸°íšŒë“¤ì´ ìˆê³ , í˜‘ì˜ ì¤‘ì¸ í›¨ì”¬ ë” ê¸´ ê¸°íšŒ ëª©ë¡ë„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í˜¸ì£¼ì—ì„œ ì¶”ê°€ ì„±ì¥ì„ ìœ„í•œ ì •ë§ ì¢‹ì€ ê¸°íšŒê°€ ë§ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤.</td></tr>
<tr><td>Charles Hall: Peel Hunt LLP, Research Division That's great. And is there anything to highlight from the Sydney acquisition?</td><td>**Charles Hall:** ì‹œë“œë‹ˆ ì¸ìˆ˜ì™€ ê´€ë ¨í•´ì„œ íŠ¹ë³„íˆ ê°•ì¡°í•  ë§Œí•œ ë¶€ë¶„ì´ ìˆë‚˜ìš”?</td></tr>
<tr><td>CFO & Director: I think the main highlight for us is we were -- I mean, it's a decent group of practice in Sydney, the capital in Australia. What we were slightly -- we knew it was a premium asset. But actually, when we made the acquisition, there were a number of people even in the U.K. that said, we are aware of that group of practices, and it's really pleasing to see that you've acquired it and it's part of your portfolio. So I think, for us, what we have been seeing is as we acquire premium assets, veterinary is quite a small community. Vendors will speak to other colleagues, and we're finding that we're getting an increased kind of inbound traffic now into us in terms of potential further opportunity to acquire their practices in due course.</td><td>**CFO & Director:** ì €í¬ì—ê²Œ ê°€ì¥ ì£¼ëª©í•  ë§Œí•œ ì ì€ í˜¸ì£¼ ìˆ˜ë„ì— ìˆëŠ” ì‹œë“œë‹ˆì˜ ìƒë‹¹íˆ ê´œì°®ì€ ì§„ë£Œì†Œ ê·¸ë£¹ì„ ì¸ìˆ˜í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ê²ƒì´ í”„ë¦¬ë¯¸ì—„ ìì‚°ì´ë¼ëŠ” ê²ƒì„ ì•Œê³  ìˆì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹¤ì œë¡œ ì¸ìˆ˜ë¥¼ ì§„í–‰í–ˆì„ ë•Œ, ì˜êµ­ì— ìˆëŠ” ë§ì€ ì‚¬ëŒë“¤ì´ ì €í¬ì—ê²Œ ê·¸ ì§„ë£Œì†Œ ê·¸ë£¹ì„ ì•Œê³  ìˆë‹¤ê³  ë§í•˜ë©´ì„œ, ê·€í•˜ê°€ ê·¸ê²ƒì„ ì¸ìˆ˜í•´ì„œ í¬íŠ¸í´ë¦¬ì˜¤ì— í¬í•¨ì‹œí‚¨ ê²ƒì„ ë³´ë‹ˆ ì •ë§ ê¸°ì˜ë‹¤ê³  í–ˆìŠµë‹ˆë‹¤.<br><br>ì €í¬ê°€ ë³´ê³  ìˆëŠ” ê²ƒì€ í”„ë¦¬ë¯¸ì—„ ìì‚°ì„ ì¸ìˆ˜í• ìˆ˜ë¡ ìˆ˜ì˜í•™ê³„ê°€ ìƒë‹¹íˆ ì‘ì€ ì»¤ë®¤ë‹ˆí‹°ë¼ëŠ” ì ì…ë‹ˆë‹¤. ë§¤ë„ìë“¤ì´ ë‹¤ë¥¸ ë™ë£Œë“¤ê³¼ ì´ì•¼ê¸°ë¥¼ ë‚˜ëˆ„ê²Œ ë˜ê³ , ì €í¬ì—ê²Œ ë“¤ì–´ì˜¤ëŠ” ì¸ë°”ìš´ë“œ íŠ¸ë˜í”½ì´ ì¦ê°€í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ë°œê²¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. í–¥í›„ ê·¸ë“¤ì˜ ì§„ë£Œì†Œë¥¼ ì¸ìˆ˜í•  ìˆ˜ ìˆëŠ” ì ì¬ì ì¸ ê¸°íšŒë“¤ ë§ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Kane Slutzkin: Deutsche Bank AG, Research Division Kane Slutzkin from Deutsche. Just, guys, on the sort of exit rates going to '26. You've obviously spoken about a better second half. It looks like vet practices did sort of 2% in the second. But could you just talk about that exit rate going into this year, bearing in mind the Q4 comp was relatively soft for the cyber event? So anything you could help us with there? And following on from that, sort of just thinking more medium term, the 4% to 8%, you're still kind of reiterating as a target. I appreciate timing is uncertain. But what do you need to do to build back up to there?</td><td>**Kane Slutzkin:** ë„ì´ì²´ì€í–‰ ë¦¬ì„œì¹˜ ë¶€ë¬¸ì˜ ì¼€ì¸ ìŠ¬ëŸ¬ì¸ í‚¨ì…ë‹ˆë‹¤. 26ë…„ìœ¼ë¡œ ê°€ëŠ” ì¶œêµ¬ ì„±ì¥ë¥ ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í•˜ë°˜ê¸°ê°€ ë” ë‚˜ì„ ê²ƒì´ë¼ê³  ë§ì”€í•˜ì…¨ëŠ”ë°, ìˆ˜ì˜ì‚¬ ì§„ë£Œì†Œ ì‚¬ì—…ì´ 2ë¶„ê¸°ì— ì•½ 2% ì„±ì¥í•œ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì‚¬ì´ë²„ ì‚¬ê±´ìœ¼ë¡œ ì¸í•´ 4ë¶„ê¸° ê¸°ì €íš¨ê³¼ê°€ ìƒëŒ€ì ìœ¼ë¡œ ë‚®ì•˜ë˜ ì ì„ ê³ ë ¤í•  ë•Œ, ì˜¬í•´ë¡œ ë“¤ì–´ê°€ëŠ” ì¶œêµ¬ ì„±ì¥ë¥ ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ ë¶€ë¶„ì— ëŒ€í•´ ë„ì›€ì„ ì£¼ì‹¤ ìˆ˜ ìˆëŠ” ë‚´ìš©ì´ ìˆë‹¤ë©´ ë§ì”€í•´ ì£¼ì„¸ìš”.<br><br>ê·¸ë¦¬ê³  ì´ì–´ì„œ, ì¤‘ê¸°ì ìœ¼ë¡œ ìƒê°í•´ë³´ë©´ 4%ì—ì„œ 8%ë¼ëŠ” ëª©í‘œë¥¼ ì—¬ì „íˆ ì¬í™•ì¸í•˜ê³  ê³„ì‹ ë°ìš”. íƒ€ì´ë°ì´ ë¶ˆí™•ì‹¤í•˜ë‹¤ëŠ” ì ì€ ì´í•´í•©ë‹ˆë‹¤ë§Œ, ê·¸ ìˆ˜ì¤€ê¹Œì§€ ë‹¤ì‹œ ì„±ì¥í•˜ê¸° ìœ„í•´ì„œëŠ” ë¬´ì—‡ì„ í•´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>CEO & Director: Yes. And maybe I'll pick the second part first and Robin can pick up the first part. But in terms of our 4% to 8% medium-term ambition, absolutely, we are committed to that and confident we can get back to that level. I guess a number of factors at play there. One is hopefully improved consumer confidence in the U.K. We all eagerly await the announcement in November in the latest budget. But it does feel like consumer confidence is slowly returning, but we want that to continue. Certainty from the CMA process, I think, will help because the scrutiny the sector has been under over the last couple of years and some of the kind of press articles haven't helped the sector. And then there's the cohort of puppies and kittens born in their peak COVID period that are now typically kind of healthy animals, kind of 4 or 5 years old. But we all know they will age and, as like humans, more things go wrong in later life and more clinical care is required. So there's that kind of tailwind, if you excuse the pun, that will benefit our numbers in due course. In terms of the final quarter and leading into the first quarter of the new financial year, maybe just ask Robin to give a bit more color.</td><td>**CEO & Director:** ë„¤, ë‘ ë²ˆì§¸ ë¶€ë¶„ë¶€í„° ë¨¼ì € ë§ì”€ë“œë¦¬ê³  Robinì´ ì²« ë²ˆì§¸ ë¶€ë¶„ì„ ë‹¤ë£¨ê² ìŠµë‹ˆë‹¤. 4%ì—ì„œ 8%ì˜ ì¤‘ê¸° ëª©í‘œì™€ ê´€ë ¨í•´ì„œëŠ” ì ˆëŒ€ì ìœ¼ë¡œ ê·¸ ëª©í‘œì— ì „ë…í•˜ê³  ìˆìœ¼ë©° ê·¸ ìˆ˜ì¤€ìœ¼ë¡œ ëŒì•„ê°ˆ ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. ì—¬ëŸ¬ ìš”ì¸ë“¤ì´ ì‘ìš©í•˜ê³  ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. <br><br>í•˜ë‚˜ëŠ” ì˜êµ­ ë‚´ ì†Œë¹„ì ì‹ ë¢°ë„ ê°œì„ ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ ëª¨ë‘ 11ì›” ìµœì‹  ì˜ˆì‚° ë°œí‘œë¥¼ ê°„ì ˆíˆ ê¸°ë‹¤ë¦¬ê³  ìˆìŠµë‹ˆë‹¤. ì†Œë¹„ì ì‹ ë¢°ë„ê°€ ì„œì„œíˆ íšŒë³µë˜ê³  ìˆëŠ” ê²ƒ ê°™ì§€ë§Œ, ì´ê²ƒì´ ê³„ì†ë˜ê¸°ë¥¼ ë°”ëë‹ˆë‹¤. <br><br>CMA(ê²½ìŸì‹œì¥ì²­) ì ˆì°¨ì—ì„œ ë‚˜ì˜¤ëŠ” í™•ì‹¤ì„±ë„ ë„ì›€ì´ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë…„ê°„ ì´ ì—…ê³„ê°€ ë°›ì•„ì˜¨ ë©´ë°€í•œ ì¡°ì‚¬ì™€ ì¼ë¶€ ì–¸ë¡  ê¸°ì‚¬ë“¤ì´ ì—…ê³„ì— ë„ì›€ì´ ë˜ì§€ ì•Šì•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì½”ë¡œë‚˜19 ì ˆì •ê¸°ì— íƒœì–´ë‚œ ê°•ì•„ì§€ì™€ ê³ ì–‘ì´ë“¤ì´ ìˆëŠ”ë°, ì´ë“¤ì€ í˜„ì¬ ë³´í†µ 4-5ì„¸ ì •ë„ì˜ ê±´ê°•í•œ ë™ë¬¼ë“¤ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ ëª¨ë‘ ì•Œê³  ìˆë“¯ì´ ì´ë“¤ë„ ë‚˜ì´ê°€ ë“¤ë©´ì„œ, ì¸ê°„ê³¼ ë§ˆì°¬ê°€ì§€ë¡œ í›„ë…„ì— ë” ë§ì€ ë¬¸ì œê°€ ë°œìƒí•˜ê³  ë” ë§ì€ ì„ìƒ ì¹˜ë£Œê°€ í•„ìš”í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ë§ì¥ë‚œì„ ìš©ì„œí•´ ì£¼ì‹ ë‹¤ë©´, ì´ëŸ° ìˆœí’ì´ í–¥í›„ ìš°ë¦¬ ì‹¤ì ì— ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤. 4ë¶„ê¸°ì™€ ìƒˆ íšŒê³„ì—°ë„ 1ë¶„ê¸° ì „ë§ì— ëŒ€í•´ì„œëŠ” ë¡œë¹ˆì´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CFO & Director: Yes. So Ken, we haven't shared like-for-like number in terms of the year-to-date like-for-like percentage growth. But we have given some, I suppose, data points. H1 was minus 1.1%. We said we didn't return to growth until Q4 and the full year landed at positive 0.2%. So simple math would dictate, we saw probably underlying 2% to 3% growth through the final quarter. And yes, we had a cyber event in that final quarter in our comparatives, but it's pleasing to see that growth continue into the new year.</td><td>**CFO & Director:** ë„¤, ì¼„. ì—°ì´ˆ ëŒ€ë¹„ ë™ì¼ ë§¤ì¥ ì„±ì¥ë¥ (like-for-like) ìˆ˜ì¹˜ëŠ” ë³„ë„ë¡œ ê³µìœ í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ëª‡ ê°€ì§€ ë°ì´í„° í¬ì¸íŠ¸ëŠ” ì œê³µí–ˆì£ . ìƒë°˜ê¸°ëŠ” ë§ˆì´ë„ˆìŠ¤ 1.1%ì˜€ê³ , 4ë¶„ê¸°ê¹Œì§€ëŠ” ì„±ì¥ì„¸ë¡œ ëŒì•„ì„œì§€ ëª»í–ˆë‹¤ê°€ ì—°ê°„ ì „ì²´ë¡œëŠ” í”ŒëŸ¬ìŠ¤ 0.2%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ê°„ë‹¨í•œ ê³„ì‚°ìœ¼ë¡œ ë³´ë©´, ë§ˆì§€ë§‰ ë¶„ê¸°ì—ëŠ” ê¸°ì € ì„±ì¥ë¥ ì´ ëŒ€ëµ 2%ì—ì„œ 3% ì •ë„ì˜€ì„ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  ë§ìŠµë‹ˆë‹¤, ë§ˆì§€ë§‰ ë¶„ê¸° ë¹„êµ ê¸°ì¤€ì— ì‚¬ì´ë²„ ì‚¬ê±´ì´ ìˆì—ˆì£ . í•˜ì§€ë§Œ ê·¸ ì„±ì¥ì„¸ê°€ ì‹ ë…„ë„ê¹Œì§€ ì´ì–´ì§€ê³  ìˆë‹¤ëŠ” ì ì€ ê³ ë¬´ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Kane Slutzkin: Deutsche Bank AG, Research Division And maybe just one quick one. Just thinking now, we've got the guide is sort of -- seems consistent with consensus. Just wondering sort of how much inorganic growth -- I mean, I probably need to do the numbers myself, but while I'm here, if you could help me. Just sort of post period end acquisition, the bigger one you've announced, how much revenue and EBITDA is that? Is it sort of like GBP 10 million to GBP 15 million of rev and maybe GBP 2 million, GBP 3 million of EBITDA? I'm just trying to get a sense of how much -- it's becoming a little bit tricky now with all the acquisitions to kind of see what underlying is really nowadays. But yes, anything you can help me with there?</td><td>**Kane Slutzkin:** ê°€ì´ë˜ìŠ¤ê°€ ì»¨ì„¼ì„œìŠ¤ì™€ ì¼ì¹˜í•˜ëŠ” ê²ƒ ê°™ì€ë°, ë¬´ê¸°ì  ì„±ì¥ì´ ì–¼ë§ˆë‚˜ ë˜ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì œê°€ ì§ì ‘ ê³„ì‚°í•´ì•¼ í•  ê²ƒ ê°™ì§€ë§Œ, ì´ ê¸°íšŒì— ë„ì›€ì„ ë°›ì„ ìˆ˜ ìˆë‹¤ë©´ìš”. ê¸°ê°„ ì¢…ë£Œ í›„ ì¸ìˆ˜í•©ë³‘ ì¤‘ì—ì„œ ë°œí‘œí•˜ì‹  í° ê±´ì´ ë§¤ì¶œê³¼ EBITDAì— ì–¼ë§ˆë‚˜ ê¸°ì—¬í• ê¹Œìš”? ëŒ€ëµ ë§¤ì¶œ 1,000ë§Œ~1,500ë§Œ íŒŒìš´ë“œ, EBITDA 200ë§Œ~300ë§Œ íŒŒìš´ë“œ ì •ë„ ë ê¹Œìš”? ì¸ìˆ˜í•©ë³‘ì´ ë§ì•„ì§€ë©´ì„œ ì‹¤ì œ ê¸°ì € ì„±ì¥ë¥ ì„ íŒŒì•…í•˜ê¸°ê°€ ì¡°ê¸ˆ ê¹Œë‹¤ë¡œì›Œì§€ê³  ìˆì–´ì„œìš”. ì´ ë¶€ë¶„ì— ëŒ€í•´ ë„ì›€ì„ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?</td></tr>
<tr><td>CFO & Director: Yes. Well, maybe if I just provide you EBITDA numbers, if that's okay. So we spent GBP 23 million in year-to-date. I think we've shared before multiples in Australia are good. They are accretive levels. So it's about 8x multiple-ish on average, sometimes a little bit less, sometimes a little bit more. That would be about GBP 2 million to GBP 3 million annualized EBITDA. We did -- some of those acquisitions were made towards the back end of the quarter. So you just have to then prorate that.</td><td>**CFO & Director:** ë„¤, EBITDA ìˆ˜ì¹˜ë¡œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì—°ì´ˆ ëŒ€ë¹„ 2ì²œ 300ë§Œ íŒŒìš´ë“œë¥¼ ì§€ì¶œí–ˆìŠµë‹ˆë‹¤. ì´ì „ì—ë„ ë§ì”€ë“œë ¸ë“¯ì´ í˜¸ì£¼ì˜ ë°°ìˆ˜ëŠ” ì–‘í˜¸í•˜ê³  ê°€ì‚°ì ì¸ ìˆ˜ì¤€ì…ë‹ˆë‹¤. í‰ê· ì ìœ¼ë¡œ ì•½ 8ë°° ë°°ìˆ˜ ì •ë„ì´ë©°, ë•Œë¡œëŠ” ì¡°ê¸ˆ ë‚®ê¸°ë„ í•˜ê³  ë•Œë¡œëŠ” ì¡°ê¸ˆ ë†’ê¸°ë„ í•©ë‹ˆë‹¤. ì´ëŠ” ì—°ê°„ EBITDA ê¸°ì¤€ìœ¼ë¡œ ì•½ 200ë§Œì—ì„œ 300ë§Œ íŒŒìš´ë“œ ì •ë„ì— í•´ë‹¹í•©ë‹ˆë‹¤. ì¼ë¶€ ì¸ìˆ˜ëŠ” ë¶„ê¸° í›„ë°˜ë¶€ì— ì´ë£¨ì–´ì¡Œê¸° ë•Œë¬¸ì— ì´ë¥¼ ë¹„ë¡€ ë°°ë¶„í•´ì„œ ê³„ì‚°í•˜ì…”ì•¼ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: And in terms of revenue, we've said margins in Australia is slightly better than the group. So you can perhaps solve that, yes.</td><td>**CEO & Director:** ë§¤ì¶œ ì¸¡ë©´ì—ì„œ ë³´ë©´, í˜¸ì£¼ì˜ ë§ˆì§„ì´ ê·¸ë£¹ ì „ì²´ë³´ë‹¤ ì•½ê°„ ë” ì¢‹ë‹¤ê³  ë§ì”€ë“œë¦° ë°” ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆ ì´ë¥¼ í†µí•´ ê³„ì‚°í•´ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Whitney: Investec Bank plc, Research Division It's Andrew from Investec. Just following up on those questions actually. One on Australia. Do you have a sense what the rate of the market consolidation is there? I know the presentation says you're sort of 15% to 20% market consolidated. And what I'm trying to do there is just understand how much runway until we get to a situation similar to where we are in the U.K., right? And then obviously, being an analyst looking further, are there other -- or at what stage do you start to think about other geographies when you're comfortable that Australia is going in the way that you want? So that's question one. And then just following up on Kane's question on 4% to 8% like-for-like growth rate. Just trying to understand what the drivers are in the same way Kane was. Is that a continued value accretion? Are you continuing in with contextualized care? I'm just trying to think about what the answer is. Is it value, volume, mix? What's the big driver in getting to 4% to 8%?</td><td>**Andrew Whitney:** í˜¸ì£¼ì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì‹œì¥ í†µí•© ì†ë„ì— ëŒ€í•œ ê°ê°ì´ ìˆìœ¼ì‹ ì§€ìš”? ë°œí‘œ ìë£Œì—ì„œ ì•½ 15%ì—ì„œ 20% ì •ë„ ì‹œì¥ì´ í†µí•©ë˜ì—ˆë‹¤ê³  í•˜ì…¨ëŠ”ë°, ì œê°€ ì´í•´í•˜ê³ ì í•˜ëŠ” ê²ƒì€ ì˜êµ­ê³¼ ìœ ì‚¬í•œ ìƒí™©ì— ë„ë‹¬í•˜ê¸°ê¹Œì§€ ì–¼ë§ˆë‚˜ ë” ì—¬ìœ ê°€ ìˆëŠ”ì§€ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¹ì—°íˆ ì• ë„ë¦¬ìŠ¤íŠ¸ë¡œì„œ ë” ë©€ë¦¬ ë‚´ë‹¤ë³´ë©´, í˜¸ì£¼ê°€ ì›í•˜ì‹œëŠ” ë°©í–¥ìœ¼ë¡œ ì§„í–‰ë˜ê³  ìˆë‹¤ê³  í™•ì‹ í•˜ì‹¤ ë•Œ ë‹¤ë¥¸ ì§€ì—­ë“¤ì„ ê³ ë ¤í•˜ê¸° ì‹œì‘í•˜ëŠ” ë‹¨ê³„ëŠ” ì–¸ì œì¸ì§€, ì•„ë‹ˆë©´ ë‹¤ë¥¸ ì§€ì—­ë“¤ì´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì´ê²ƒì´ ì²« ë²ˆì§¸ ì§ˆë¬¸ì…ë‹ˆë‹¤.<br><br>ê·¸ë¦¬ê³  Kaneì´ ì§ˆë¬¸í–ˆë˜ 4%ì—ì„œ 8% ë™ì¼ì¡°ê±´ ì„±ì¥ë¥ ì— ëŒ€í•´ í›„ì† ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ì¼€ì¸ì´ ì§ˆë¬¸í–ˆë˜ ê²ƒê³¼ ê°™ì€ ë§¥ë½ì—ì„œ ë™ë ¥ì´ ë¬´ì—‡ì¸ì§€ ì´í•´í•˜ë ¤ê³  í•©ë‹ˆë‹¤. ì§€ì†ì ì¸ ê°€ì¹˜ ì¦ëŒ€ì¸ê°€ìš”? ë§ì¶¤í˜• ì¼€ì–´ë¥¼ ê³„ì† í™•ëŒ€í•˜ëŠ” ê±´ê°€ìš”? ë‹µì´ ë¬´ì—‡ì¸ì§€ íŒŒì•…í•˜ë ¤ê³  í•˜ëŠ”ë°ìš”. ê°€ì¹˜ì¸ì§€, ë¬¼ëŸ‰ì¸ì§€, ë¯¹ìŠ¤ì¸ì§€ìš”? 4%ì—ì„œ 8% ì„±ì¥ë¥ ì„ ë‹¬ì„±í•˜ëŠ” ë° ìˆì–´ ê°€ì¥ í° ë™ë ¥ì´ ë¬´ì—‡ì¸ê°€ìš”?</td></tr>
<tr><td>CEO & Director: Yes. And Paul, do you want to start with that part? And I'll pick up the first part of the question.</td><td>**CEO & Director:** ë„¤, í´ì´ ê·¸ ë¶€ë¶„ë¶€í„° ì‹œì‘í•´ì£¼ì‹œê² ì–´ìš”? ê·¸ëŸ¬ë©´ ì œê°€ ì§ˆë¬¸ì˜ ì²« ë²ˆì§¸ ë¶€ë¶„ì„ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Veterinary Officer: Yes. I think you pick up a great point around how do you create that value. And we've got a big focus at the moment on client experience. And that's because as a profession, perhaps we've had a great focus on our ability to deliver fantastic care for animals, and I think we need to progress how we give that care to our clients, our pet owners in particular as well and really demonstrate the value of the care that we provide. So I have absolutely no doubt that our colleagues provide the best clinical care they possibly can. We can absolutely demonstrate that and demonstrate that value to our clients, and that's work that we're continuously doing. So I think that is a big action that we're taking at the moment, driving confidence in the consulting room. We have our new graduate program now. We have a new consulting skills program, which enables that communication with a real refocus from not necessarily a clinical outcome being the right outcome but shared decision-making, so ensuring that our pet owners leave that room with the absolute confidence they've made the right decision for them and for their animal, which is a slightly different shift potentially to always making the right diagnosis. It's a subtle reframing but it's an important one.</td><td>**Chief Veterinary Officer:** ë„¤, ê°€ì¹˜ ì°½ì¶œ ë°©ë²•ì— ëŒ€í•œ í›Œë¥­í•œ ì§€ì ì„ í•´ì£¼ì…¨ìŠµë‹ˆë‹¤. í˜„ì¬ ì €í¬ëŠ” ê³ ê° ê²½í—˜ì— í° ì¤‘ì ì„ ë‘ê³  ìˆìŠµë‹ˆë‹¤. ìˆ˜ì˜í•™ ì „ë¬¸ì§ìœ¼ë¡œì„œ ë™ë¬¼ë“¤ì—ê²Œ í›Œë¥­í•œ ì¹˜ë£Œë¥¼ ì œê³µí•˜ëŠ” ëŠ¥ë ¥ì—ëŠ” ë›°ì–´ë‚œ ì—­ëŸ‰ì„ ë³´ì—¬ì™”ì§€ë§Œ, ì´ì œëŠ” ê³ ê°ë“¤, íŠ¹íˆ ë°˜ë ¤ë™ë¬¼ ì†Œìœ ìë“¤ì—ê²Œ ê·¸ ì¹˜ë£Œë¥¼ ì–´ë–»ê²Œ ì œê³µí•˜ëŠ”ì§€ì— ëŒ€í•´ì„œë„ ë°œì „ì‹œì¼œì•¼ í•˜ê³ , ì €í¬ê°€ ì œê³µí•˜ëŠ” ì¹˜ë£Œì˜ ê°€ì¹˜ë¥¼ ì‹¤ì œë¡œ ì…ì¦í•´ì•¼ í•œë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ì €í¬ ë™ë£Œë“¤ì´ ê°€ëŠ¥í•œ ìµœê³ ì˜ ì„ìƒ ì¹˜ë£Œë¥¼ ì œê³µí•œë‹¤ëŠ” ì ì— ëŒ€í•´ì„œëŠ” ì „í˜€ ì˜ì‹¬í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê·¸ê²ƒì„ í™•ì‹¤íˆ ì…ì¦í•  ìˆ˜ ìˆê³ , ê³ ê°ë“¤ì—ê²Œ ê·¸ ê°€ì¹˜ë¥¼ ë³´ì—¬ì¤„ ìˆ˜ ìˆìœ¼ë©°, ì´ëŠ” ì €í¬ê°€ ì§€ì†ì ìœ¼ë¡œ í•˜ê³  ìˆëŠ” ì‘ì—…ì…ë‹ˆë‹¤. ë”°ë¼ì„œ í˜„ì¬ ì €í¬ê°€ ì·¨í•˜ê³  ìˆëŠ” í° í–‰ë™ ì¤‘ í•˜ë‚˜ê°€ ì§„ë£Œì‹¤ì—ì„œì˜ ì‹ ë¢°ë„ë¥¼ ë†’ì´ëŠ” ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ì œ ì €í¬ì—ê²ŒëŠ” ìƒˆë¡œìš´ ì‹ ì… í”„ë¡œê·¸ë¨ë„ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ìƒˆë¡œìš´ ì»¨ì„¤íŒ… ìŠ¤í‚¬ í”„ë¡œê·¸ë¨ì„ ë„ì…í–ˆëŠ”ë°, ì´ëŠ” ì„ìƒ ê²°ê³¼ê°€ ë°˜ë“œì‹œ ì˜¬ë°”ë¥¸ ê²°ê³¼ë¼ëŠ” ê´€ì ì—ì„œ ë²—ì–´ë‚˜ ê³µë™ ì˜ì‚¬ê²°ì •ì— ì¤‘ì ì„ ë‘” ì†Œí†µì„ ê°€ëŠ¥í•˜ê²Œ í•©ë‹ˆë‹¤. ë°˜ë ¤ë™ë¬¼ ì£¼ì¸ë“¤ì´ ì§„ë£Œì‹¤ì„ ë‚˜ì„¤ ë•Œ ìì‹ ê³¼ ë°˜ë ¤ë™ë¬¼ì„ ìœ„í•´ ì˜¬ë°”ë¥¸ ê²°ì •ì„ ë‚´ë ¸ë‹¤ëŠ” ì ˆëŒ€ì ì¸ í™•ì‹ ì„ ê°–ë„ë¡ í•˜ëŠ” ê²ƒì´ì£ . ì´ëŠ” í•­ìƒ ì •í™•í•œ ì§„ë‹¨ì„ ë‚´ë¦¬ëŠ” ê²ƒê³¼ëŠ” ë‹¤ì†Œ ë‹¤ë¥¸ ì ‘ê·¼ ë°©ì‹ì…ë‹ˆë‹¤. ë¯¸ë¬˜í•œ ê´€ì ì˜ ì „í™˜ì´ì§€ë§Œ ë§¤ìš° ì¤‘ìš”í•œ ë³€í™”ì…ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: And in terms of the market share and the consolidation levels, Robin talked about the two major groups being VetPartners and Greencross. There's also a smaller private equity-owned consolidator called Vets Central. They're owned by Pemba Capital. So all three of those groups have actually more practices than we do. VetPartners is about 250; Greencross, under 200; Vets Central, I think, over 50. I think in terms of scale, given the size of our practices, we're probably third in terms of scale. But in terms of consolidation, we think the market is between 15% and 20% consolidated, so plenty of opportunity for continued expansion of CVS. We will continue to be disciplined, though, in that we want those high-quality larger sites because they derisk our entry in that if you lose a vet post acquisition, if you've got a larger team of vets, it's much easier to accrete into. And we've been pleased with the approach and performance so far. But we definitely see a strong pipeline of further opportunities. In terms of other people consolidating, there is competition for deals but probably less than it was in the U.K. a few years ago pre the CMA process.</td><td>**CEO & Director:** ì‹œì¥ ì ìœ ìœ¨ê³¼ í†µí•© ìˆ˜ì¤€ê³¼ ê´€ë ¨í•´ì„œ, Robinì´ ì–¸ê¸‰í•œ ë‘ ì£¼ìš” ê·¸ë£¹ì¸ VetPartnersì™€ Greencross ì™¸ì—ë„ Vets Centralì´ë¼ëŠ” ì†Œê·œëª¨ ì‚¬ëª¨í€ë“œ ì†Œìœ  í†µí•©ì—…ì²´ê°€ ìˆìŠµë‹ˆë‹¤. ì´ë“¤ì€ Pemba Capital ì†Œìœ ì…ë‹ˆë‹¤. ì‹¤ì œë¡œ ì´ ì„¸ ê·¸ë£¹ ëª¨ë‘ ì €í¬ë³´ë‹¤ ë” ë§ì€ ë³‘ì›ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. VetPartnersê°€ ì•½ 250ê°œ, Greencrossê°€ 200ê°œ ë¯¸ë§Œ, Vets Centralì´ 50ê°œê°€ ë„˜ëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·œëª¨ ë©´ì—ì„œëŠ” ì €í¬ ë³‘ì›ë“¤ì˜ í¬ê¸°ë¥¼ ê³ ë ¤í•  ë•Œ ì•„ë§ˆ 3ìœ„ ì •ë„ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ í†µí•© ì¸¡ë©´ì—ì„œ ë³´ë©´, ì‹œì¥ì´ 15%ì—ì„œ 20% ì •ë„ í†µí•©ë˜ì–´ ìˆë‹¤ê³  ë³´ê³  ìˆì–´ì„œ, CVSì˜ ì§€ì†ì ì¸ í™•ì¥ì„ ìœ„í•œ ê¸°íšŒëŠ” ì¶©ë¶„í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ëŠ” ê³„ì†í•´ì„œ ì‹ ì¤‘í•œ ì ‘ê·¼ì„ ìœ ì§€í•  ê²ƒì…ë‹ˆë‹¤. ê³ í’ˆì§ˆì˜ ëŒ€ê·œëª¨ ë³‘ì›ë“¤ì„ ì›í•˜ëŠ” ì´ìœ ëŠ” ì´ëŸ° ê³³ë“¤ì´ ì €í¬ì˜ ì§„ì… ë¦¬ìŠ¤í¬ë¥¼ ì¤„ì—¬ì£¼ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì¸ìˆ˜ í›„ ìˆ˜ì˜ì‚¬ í•œ ëª…ì„ ìƒë”ë¼ë„ ìˆ˜ì˜ì‚¬ íŒ€ì´ í¬ë©´ í›¨ì”¬ ì‰½ê²Œ ë³´ì¶©í•  ìˆ˜ ìˆê±°ë“ ìš”. ì§€ê¸ˆê¹Œì§€ì˜ ì ‘ê·¼ ë°©ì‹ê³¼ ì„±ê³¼ì— ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•ìœ¼ë¡œë„ ê°•ë ¥í•œ ê¸°íšŒë“¤ì´ ë§ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤.<br><br>ë‹¤ë¥¸ ì—…ì²´ë“¤ì˜ í†µí•© ì›€ì§ì„ê³¼ ê´€ë ¨í•´ì„œëŠ” ë”œ ê²½ìŸì´ ìˆê¸´ í•˜ì§€ë§Œ, ëª‡ ë…„ ì „ CMA í”„ë¡œì„¸ìŠ¤ ì´ì „ ì˜êµ­ì—ì„œë³´ë‹¤ëŠ” ê²½ìŸì´ ëœí•œ í¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Whitney: Investec Bank plc, Research Division Great. So you're not thinking you need other geographies at the moment?</td><td>**Andrew Whitney:** í˜„ì¬ë¡œì„œëŠ” ë‹¤ë¥¸ ì§€ì—­ìœ¼ë¡œì˜ í™•ì¥ì´ í•„ìš”í•˜ë‹¤ê³  ìƒê°í•˜ì§€ ì•Šìœ¼ì‹œëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>CEO & Director: Not yet. But equally, in due course, there may well be further opportunities for growth. Australia was really attractive because it's English-speaking and the approach to clinical care is very similar to the U.K. and the clinical standards are very similar. So it had very attractive features. And obviously, with low levels of consolidation, that was an added attractive feature. So that's not to say there won't be other markets in due course, but certainly not in the short term. Charles -- sorry, James?</td><td>**CEO & Director:** ì•„ì§ì€ ì•„ë‹™ë‹ˆë‹¤. í•˜ì§€ë§Œ ë§ˆì°¬ê°€ì§€ë¡œ ì ì ˆí•œ ì‹œê¸°ê°€ ë˜ë©´ ì¶”ê°€ì ì¸ ì„±ì¥ ê¸°íšŒë“¤ì´ ë¶„ëª…íˆ ìˆì„ ê²ƒì…ë‹ˆë‹¤. í˜¸ì£¼ê°€ ì •ë§ ë§¤ë ¥ì ì´ì—ˆë˜ ì´ìœ ëŠ” ì˜ì–´ê¶Œ êµ­ê°€ì´ê³  ì„ìƒ ì¹˜ë£Œì— ëŒ€í•œ ì ‘ê·¼ ë°©ì‹ì´ ì˜êµ­ê³¼ ë§¤ìš° ìœ ì‚¬í•˜ë©° ì„ìƒ ê¸°ì¤€ë„ ë¹„ìŠ·í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ë§¤ìš° ë§¤ë ¥ì ì¸ íŠ¹ì§•ë“¤ì„ ê°€ì§€ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¹ì—°íˆ ë‚®ì€ ìˆ˜ì¤€ì˜ í†µí•©ë„ ì¶”ê°€ì ì¸ ë§¤ë ¥ ìš”ì†Œì˜€ìŠµë‹ˆë‹¤. ì´ê²ƒì´ í–¥í›„ ë‹¤ë¥¸ ì‹œì¥ë“¤ì´ ì—†ì„ ê²ƒì´ë¼ëŠ” ì˜ë¯¸ëŠ” ì•„ë‹ˆì§€ë§Œ, ë‹¨ê¸°ì ìœ¼ë¡œëŠ” í™•ì‹¤íˆ ì•„ë‹™ë‹ˆë‹¤. ì°°ìŠ¤... ì£„ì†¡í•©ë‹ˆë‹¤, ì œì„ìŠ¤?</td></tr>
<tr><td>James Bayliss: Joh. Berenberg, Gossler & Co. KG, Research Division James Bayliss from Berenberg. Just two, if I may. On the online platform, can you just talk us a bit through where you are in terms of the investments you've been making to improve kind of customer click through, the migration to cloud and how you see that then driving a recovery or kind of further performance on that side of the business over the next few years? And then secondly, in the context of vets up 4.5% year-on-year organically, can you just give us an update on what the kind of the wider backdrop is in the market in terms of recruitment, perhaps the differences between the U.K. and Australia in that regard?</td><td>**James Bayliss:** ì˜¨ë¼ì¸ í”Œë«í¼ì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê³ ê° í´ë¦­ë¥  ê°œì„ ê³¼ í´ë¼ìš°ë“œ ë§ˆì´ê·¸ë ˆì´ì…˜ì„ ìœ„í•œ íˆ¬ì í˜„í™©ì— ëŒ€í•´ ì„¤ëª…ë“œë¦¬ê³ , í–¥í›„ ëª‡ ë…„ê°„ ì´ ì‚¬ì—… ë¶€ë¬¸ì˜ íšŒë³µê³¼ ì¶”ê°€ì ì¸ ì„±ê³¼ ê°œì„ ì„ ì–´ë–»ê²Œ ì „ë§í•˜ëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?<br><br>ë‘ ë²ˆì§¸ë¡œ, ìˆ˜ì˜ì‚¬ ìˆ˜ê°€ ì „ë…„ ëŒ€ë¹„ ìœ ê¸°ì ìœ¼ë¡œ 4.5% ì¦ê°€í•œ ìƒí™©ì—ì„œ, ì±„ìš© ì‹œì¥ì˜ ì „ë°˜ì ì¸ ë°°ê²½ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ë¥¼ ë¶€íƒë“œë¦½ë‹ˆë‹¤. íŠ¹íˆ ì˜êµ­ê³¼ í˜¸ì£¼ ê°„ì˜ ì°¨ì´ì ì´ ìˆë‹¤ë©´ í•¨ê»˜ ì„¤ëª…í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: And maybe Paul can pick up with the latter. In terms of the platform itself, we did invest in the first half of the last financial year in improving the Animed Direct website and the kind of customer journey. We have seen an improvement in revenue growth in the second half, and that will continue into the new financial year. But the market online is tough. We have seen some clients trade down from the premium pet food that we sell online, so the likes of Royal Canin and Hill's, et cetera. And some clients are buying kind of cheaper supermarket pet food. So there's definitely been a trade down of some clients. But we are continuing to invest in that platform, both in the experience for the client but also driving more repeat business as well. So subscriptions, for instance, is a new feature we've recently added. We will continue to try and optimize that platform. And hopefully, we do see a return to growth in the pet food side as well.</td><td>**CEO & Director:** í”Œë«í¼ ìì²´ì— ëŒ€í•´ì„œëŠ” ì§€ë‚œ íšŒê³„ì—°ë„ ìƒë°˜ê¸°ì— Animed Direct ì›¹ì‚¬ì´íŠ¸ì™€ ê³ ê° ì—¬ì • ê°œì„ ì— íˆ¬ìí–ˆìŠµë‹ˆë‹¤. í•˜ë°˜ê¸°ì— ë§¤ì¶œ ì„±ì¥ë¥ ì´ ê°œì„ ë˜ëŠ” ê²ƒì„ í™•ì¸í–ˆê³ , ì´ëŠ” ìƒˆ íšŒê³„ì—°ë„ì—ë„ ì§€ì†ë  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì˜¨ë¼ì¸ ì‹œì¥ì€ ì–´ë ¤ìš´ ìƒí™©ì…ë‹ˆë‹¤. ì¼ë¶€ ê³ ê°ë“¤ì´ ì €í¬ê°€ ì˜¨ë¼ì¸ìœ¼ë¡œ íŒë§¤í•˜ëŠ” í”„ë¦¬ë¯¸ì—„ ë°˜ë ¤ë™ë¬¼ ì‚¬ë£Œ, ì¦‰ ë¡œì–„ìºë‹Œ(Royal Canin)ì´ë‚˜ íìŠ¤(Hill's) ê°™ì€ ì œí’ˆì—ì„œ ë” ì €ë ´í•œ ëŒ€í˜•ë§ˆíŠ¸ ë°˜ë ¤ë™ë¬¼ ì‚¬ë£Œë¡œ êµ¬ë§¤ íŒ¨í„´ì„ ë°”ê¾¸ëŠ” ê²ƒì„ ëª©ê²©í–ˆìŠµë‹ˆë‹¤. ë¶„ëª…íˆ ì¼ë¶€ ê³ ê°ë“¤ì˜ ë‹¤ìš´ê·¸ë ˆì´ë“œê°€ ìˆì—ˆìŠµë‹ˆë‹¤. <br><br>í•˜ì§€ë§Œ ì €í¬ëŠ” ê³ ê° ê²½í—˜ë¿ë§Œ ì•„ë‹ˆë¼ ì¬êµ¬ë§¤ ì´‰ì§„ ì¸¡ë©´ì—ì„œë„ í•´ë‹¹ í”Œë«í¼ì— ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ êµ¬ë… ì„œë¹„ìŠ¤ëŠ” ì €í¬ê°€ ìµœê·¼ì— ì¶”ê°€í•œ ìƒˆë¡œìš´ ê¸°ëŠ¥ì…ë‹ˆë‹¤. ì €í¬ëŠ” ê³„ì†í•´ì„œ í•´ë‹¹ í”Œë«í¼ì„ ìµœì í™”í•˜ë ¤ê³  ë…¸ë ¥í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë°˜ë ¤ë™ë¬¼ ì‚¬ë£Œ ë¶€ë¬¸ì—ì„œë„ ì„±ì¥ì„¸ë¡œì˜ íšŒë³µì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Veterinary Officer: If I pick up on that in terms of the kind of feeling within the workforce, there's no doubt that there still is a workforce shortage. And the Royal College have identified that they anticipate that shortage to become less relevant within the next few years, and we're certainly seeing a continuing improvement in the number of vets working in the U.K. Some of that is an increase in the number of vets coming through vet schools. We have new vet schools that have opened in the last couple of years. And we have larger cohorts of vet students coming through. Obviously, that's contributing to our less experienced number of vets in the U.K. But we're also seeing through the activities that we undertake around caring for our colleagues that we're seeing better retention within the profession. And in fact, we've seen a much easier recruitment into some of those tougher to staff areas in the country, so a lower reliance on locums, for example. And I think that increase of 4.5% really reflects on that, that actually we're able to recruit into some of these more challenging areas now.</td><td>**Chief Veterinary Officer:** ì¸ë ¥ ë‚´ë¶€ì˜ ë¶„ìœ„ê¸°ë¥¼ ì‚´í´ë³´ë©´, ì—¬ì „íˆ ì¸ë ¥ ë¶€ì¡± ìƒí™©ì´ ìˆëŠ” ê²ƒì€ ë¶„ëª…í•©ë‹ˆë‹¤. ì™•ë¦½ìˆ˜ì˜ëŒ€í•™ì—ì„œëŠ” ì´ëŸ¬í•œ ë¶€ì¡± í˜„ìƒì´ í–¥í›„ ëª‡ ë…„ ë‚´ì— ëœ ì‹¬ê°í•´ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•œë‹¤ê³  ë°í˜”ìœ¼ë©°, ì‹¤ì œë¡œ ì˜êµ­ì—ì„œ ê·¼ë¬´í•˜ëŠ” ìˆ˜ì˜ì‚¬ ìˆ˜ê°€ ì§€ì†ì ìœ¼ë¡œ ì¦ê°€í•˜ê³  ìˆëŠ” ê²ƒì„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì´ëŠ” ë¶€ë¶„ì ìœ¼ë¡œ ìˆ˜ì˜ê³¼ëŒ€í•™ì„ ì¡¸ì—…í•˜ëŠ” ìˆ˜ì˜ì‚¬ ìˆ˜ê°€ ì¦ê°€í•œ ë•ë¶„ì…ë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë…„ê°„ ìƒˆë¡œìš´ ìˆ˜ì˜ê³¼ëŒ€í•™ë“¤ì´ ê°œêµí–ˆê³ , ë” ë§ì€ ìˆ˜ì˜í•™ê³¼ í•™ìƒë“¤ì´ ì¡¸ì—…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì´ë¡œ ì¸í•´ ì˜êµ­ ë‚´ ê²½í—˜ì´ ë¶€ì¡±í•œ ìˆ˜ì˜ì‚¬ë“¤ì˜ ë¹„ì¤‘ì´ ëŠ˜ì–´ë‚˜ê³  ìˆëŠ” ê²ƒë„ ì‚¬ì‹¤ì…ë‹ˆë‹¤.<br><br>í•˜ì§€ë§Œ ë™ì‹œì— ìš°ë¦¬ê°€ ë™ë£Œë“¤ì„ ëŒë³´ê¸° ìœ„í•´ ì¶”ì§„í•˜ê³  ìˆëŠ” ë‹¤ì–‘í•œ í™œë™ë“¤ì„ í†µí•´ ì—…ê³„ ë‚´ ì¸ë ¥ ìœ ì§€ìœ¨ì´ ê°œì„ ë˜ê³  ìˆëŠ” ê²ƒë„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì „êµ­ì˜ ì¸ë ¥ ì¶©ì›ì´ ì–´ë ¤ì› ë˜ ì§€ì—­ë“¤ì—ì„œ ì±„ìš©ì´ í›¨ì”¬ ìˆ˜ì›”í•´ì¡Œê³ , ì˜ˆë¥¼ ë“¤ì–´ ì„ì‹œ ì˜ë£Œì§„ì— ëŒ€í•œ ì˜ì¡´ë„ê°€ ë‚®ì•„ì¡ŒìŠµë‹ˆë‹¤. 4.5% ì¦ê°€ëŠ” ë°”ë¡œ ì´ëŸ° ì ì„ ë°˜ì˜í•œ ê²ƒìœ¼ë¡œ, ì´ì œ ì´ëŸ° ì–´ë ¤ìš´ ì§€ì—­ë“¤ì—ë„ ì¸ë ¥ì„ ì¶©ì›í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>Charles Weston: RBC Capital Markets, Research Division Charles Weston from RBC. A clarification question first, please. In terms of the guidance for this year, you said you're happy with consensus, which I think is GBP 141 million for EBITDA. Is that including the acquisitions that you've made in the first couple of months or excluding them?</td><td>**Charles Weston:** RBC ìºí”¼í„¸ ë§ˆì¼“ì˜ ì°°ìŠ¤ ì›¨ìŠ¤í„´ì…ë‹ˆë‹¤. ë¨¼ì € ëª…í™•íˆ í•˜ê³  ì‹¶ì€ ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ê°€ì´ë˜ìŠ¤ì™€ ê´€ë ¨í•´ì„œ, ì»¨ì„¼ì„œìŠ¤ì— ë§Œì¡±í•œë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°, EBITDA 1ì–µ 4,100ë§Œ íŒŒìš´ë“œë¥¼ ë§ì”€í•˜ì‹œëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì˜¬í•´ ì²« ëª‡ ë‹¬ ë™ì•ˆ ì§„í–‰í•œ ì¸ìˆ˜í•©ë³‘ì„ í¬í•¨í•œ ê²ƒì¸ì§€, ì•„ë‹ˆë©´ ì œì™¸í•œ ê²ƒì¸ì§€ìš”?</td></tr>
<tr><td>CFO & Director: I mean, I can't talk for every analyst on what's included in the numbers, Charles. I'd imagine it would include some of those acquisitions, yes, is my expectation.</td><td>**CFO & Director:** ëª¨ë“  ì• ë„ë¦¬ìŠ¤íŠ¸ë“¤ì´ ìˆ˜ì¹˜ì— ë¬´ì—‡ì„ í¬í•¨ì‹œì¼°ëŠ”ì§€ëŠ” ì œê°€ ë§ì”€ë“œë¦´ ìˆ˜ ì—†ìŠµë‹ˆë‹¤, ì°°ìŠ¤. í•˜ì§€ë§Œ ê·¸ ì¸ìˆ˜í•©ë³‘ë“¤ ì¤‘ ì¼ë¶€ëŠ” í¬í•¨ë˜ì–´ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Charles Weston: RBC Capital Markets, Research Division I guess analysts probably don't include the acquisitions that you just announced. So is there...</td><td>**Charles Weston:** RBC ìºí”¼í„¸ ë§ˆì¼“ ë¦¬ì„œì¹˜ ë¶€ë¬¸ì—ì„œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì• ë„ë¦¬ìŠ¤íŠ¸ë“¤ì´ ë°©ê¸ˆ ë°œí‘œí•˜ì‹  ì¸ìˆ˜í•©ë³‘ ê±´ë“¤ì„ í¬í•¨í•˜ì§€ ì•Šì€ ê²ƒ ê°™ì€ë°ìš”. ê·¸ë ‡ë‹¤ë©´...</td></tr>
<tr><td>CFO & Director: Some may, some may not. And then they definitely don't include future acquisitions.</td><td>**CFO & Director:** ì¼ë¶€ëŠ” í¬í•¨ë  ìˆ˜ë„ ìˆê³  ì¼ë¶€ëŠ” ê·¸ë ‡ì§€ ì•Šì„ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í–¥í›„ ì¸ìˆ˜ ê±´ë“¤ì€ í™•ì‹¤íˆ í¬í•¨ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Charles Weston: RBC Capital Markets, Research Division Okay. And then secondly, just on the cyber sort of softer comps for the second half, which I think was a couple of percentage points, effectively a tailwind. Is there a tailwind from cyber in the first few months of this year that's giving you a bit of a sort of a head start on a year-on-year basis? And if you think about the 4% to 8% that you expect in the medium term and the kind of roughly 0 that you had last year, could the like-for-like be sort of halfway in the middle of this year? Where should we be thinking on the like-for-like for '26?</td><td>**Charles Weston:** ë„¤, ì‚¬ì´ë²„ ë¶€ë¬¸ì˜ í•˜ë°˜ê¸° ë¹„êµ ê¸°ì¤€ì´ ìƒëŒ€ì ìœ¼ë¡œ ë‚®ì•˜ë˜ ì ì€ ë§ì”€í•˜ì‹  ëŒ€ë¡œ ëª‡ í¼ì„¼íŠ¸ í¬ì¸íŠ¸ ì •ë„ì˜ ìˆœí’ ìš”ì¸ì´ì—ˆìŠµë‹ˆë‹¤. ì˜¬í•´ ì´ˆ ëª‡ ê°œì›” ë™ì•ˆ ì‚¬ì´ë²„ ë¶€ë¬¸ì—ì„œ ì „ë…„ ëŒ€ë¹„ ìœ ë¦¬í•œ ì¶œë°œì„ í•  ìˆ˜ ìˆëŠ” ìˆœí’ì´ ìˆëŠ”ì§€ì— ëŒ€í•œ ì§ˆë¬¸ì´êµ°ìš”.<br><br>ì¤‘ê¸°ì ìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ” 4%ì—ì„œ 8% ì„±ì¥ë¥ ê³¼ ì‘ë…„ì— ê±°ì˜ 0%ì˜€ë˜ ìƒí™©ì„ ê³ ë ¤í•  ë•Œ, ì˜¬í•´ ë™ì¼ ê¸°ì¤€ ì„±ì¥ë¥ ì´ ê·¸ ì¤‘ê°„ ì •ë„ê°€ ë  ìˆ˜ ìˆëŠ”ì§€ ê¶ê¸ˆí•´í•˜ì‹œëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. 2026ë…„ ë™ì¼ ê¸°ì¤€ ì„±ì¥ë¥ ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>CEO & Director: Yes. I think the start of this year, the comp is far less soft than it was in the final quarter. I think the one disruption that we continue to face maybe in the first quarter of last financial year was that our teams are still getting used to their new practice management system. But by and large, that disruption was far less. The peak period of disruption and, therefore, softer comp was the final quarter when we had the cyber incident and then we rapidly migrated onto a new platform. And Paul can maybe comment on how vets are finding that system now.</td><td>**CEO & Director:** ë„¤, ì˜¬í•´ ì´ˆì˜ ë¹„êµ ê¸°ì¤€ì€ ë§ˆì§€ë§‰ ë¶„ê¸°ë³´ë‹¤ í›¨ì”¬ ëœ ë¶€ë“œëŸ¬ì› ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì§€ë‚œ íšŒê³„ì—°ë„ 1ë¶„ê¸°ì— ê³„ì† ì§ë©´í–ˆë˜ í•œ ê°€ì§€ ì°¨ì§ˆì€ ì €í¬ íŒ€ë“¤ì´ ìƒˆë¡œìš´ ì§„ë£Œ ê´€ë¦¬ ì‹œìŠ¤í…œì— ì•„ì§ ì ì‘í•˜ê³  ìˆì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì „ë°˜ì ìœ¼ë¡œ ê·¸ ì°¨ì§ˆì€ í›¨ì”¬ ì ì—ˆìŠµë‹ˆë‹¤. ì°¨ì§ˆì˜ ì •ì ì´ì—ˆê³ , ë”°ë¼ì„œ ë¹„êµ ê¸°ì¤€ì´ ê°€ì¥ ë¶€ë“œëŸ¬ì› ë˜ ì‹œê¸°ëŠ” ì‚¬ì´ë²„ ì‚¬ê³ ê°€ ë°œìƒí–ˆë˜ ë§ˆì§€ë§‰ ë¶„ê¸°ì˜€ìœ¼ë©°, ê·¸ë•Œ ì €í¬ëŠ” ì‹ ì†í•˜ê²Œ ìƒˆë¡œìš´ í”Œë«í¼ìœ¼ë¡œ ì´ì „í–ˆìŠµë‹ˆë‹¤. Paulì´ ìˆ˜ì˜ì‚¬ë“¤ì´ í˜„ì¬ ê·¸ ì‹œìŠ¤í…œì„ ì–´ë–»ê²Œ ìƒê°í•˜ëŠ”ì§€ì— ëŒ€í•´ ì–¸ê¸‰í•´ ì¤„ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Veterinary Officer: Yes. I mean, early adoption is always a challenge. But actually, you really only took 6 weeks to roll the majority of our practice out onto that, so very much within the end of the last financial year and previous financial year. Now we're seeing significant engagement with that. In fact, I think we asked our colleagues now how they would -- whether they would prefer this system versus the previous system. Hands down, they would prefer this system. It enables a much wider access to client records. For example, if you work in one of our night services now, you can access the records from any of our practices that are sending cases in, whereas previously that wouldn't have been possible overnight. So it's definitely freed up an awful lot for our colleagues. There are efficiencies within that system. So for example, there's a function there which is simply called Forms, which is a really simple way to input your clinical data and to also formulate that into, for example, a discharge sheet. So actually it's now bringing significant efficiencies into practice.</td><td>**Chief Veterinary Officer:** ë„¤, ì´ˆê¸° ë„ì…ì€ í•­ìƒ ì–´ë ¤ìš´ ê³¼ì œì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹¤ì œë¡œëŠ” ìš°ë¦¬ ì§„ë£Œì†Œ ëŒ€ë¶€ë¶„ì„ ì´ ì‹œìŠ¤í…œìœ¼ë¡œ ì „í™˜í•˜ëŠ” ë° ë‹¨ 6ì£¼ë°–ì— ê±¸ë¦¬ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì§€ë‚œ íšŒê³„ì—°ë„ ë§ê³¼ ì „ íšŒê³„ì—°ë„ ë‚´ì— ì¶©ë¶„íˆ ì™„ë£Œí•  ìˆ˜ ìˆì—ˆì£ . í˜„ì¬ëŠ” ì´ ì‹œìŠ¤í…œì— ëŒ€í•œ ìƒë‹¹í•œ ì°¸ì—¬ë„ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì‚¬ì‹¤ ë™ë£Œë“¤ì—ê²Œ ì´ ì‹œìŠ¤í…œê³¼ ì´ì „ ì‹œìŠ¤í…œ ì¤‘ ì–´ëŠ ê²ƒì„ ì„ í˜¸í•˜ëŠ”ì§€ ë¬¼ì–´ë´¤ëŠ”ë°, ì••ë„ì ìœ¼ë¡œ ì´ ì‹œìŠ¤í…œì„ ì„ í˜¸í•œë‹¤ê³  ë‹µí–ˆìŠµë‹ˆë‹¤. <br><br>ì´ ì‹œìŠ¤í…œì€ ê³ ê° ê¸°ë¡ì— ëŒ€í•œ ì ‘ê·¼ì„±ì„ í›¨ì”¬ ë„“í˜€ì¤ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ì•¼ê°„ ì„œë¹„ìŠ¤ì—ì„œ ê·¼ë¬´í•˜ëŠ” ì§ì›ì´ë¼ë©´ ì´ì œ ì¼€ì´ìŠ¤ë¥¼ ë³´ë‚´ëŠ” ëª¨ë“  ì§„ë£Œì†Œì˜ ê¸°ë¡ì— ì ‘ê·¼í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ì „ì—ëŠ” ì•¼ê°„ì— ì´ëŸ° ì ‘ê·¼ì´ ë¶ˆê°€ëŠ¥í–ˆê±°ë“ ìš”. ë”°ë¼ì„œ ë™ë£Œë“¤ì—ê²Œ ì •ë§ ë§ì€ í¸ì˜ë¥¼ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. í•´ë‹¹ ì‹œìŠ¤í…œ ë‚´ì—ëŠ” íš¨ìœ¨ì„±ì´ ìˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, Formsë¼ê³  ë¶ˆë¦¬ëŠ” ê¸°ëŠ¥ì´ ìˆëŠ”ë°, ì´ëŠ” ì„ìƒ ë°ì´í„°ë¥¼ ì…ë ¥í•˜ê³  ì´ë¥¼ í‡´ì› ìš”ì•½ì„œ ê°™ì€ í˜•íƒœë¡œ ì‘ì„±í•˜ëŠ” ë§¤ìš° ê°„ë‹¨í•œ ë°©ë²•ì…ë‹ˆë‹¤. ì‹¤ì œë¡œ ì´ì œ ì§„ë£Œ í˜„ì¥ì— ìƒë‹¹í•œ íš¨ìœ¨ì„±ì„ ê°€ì ¸ë‹¤ì£¼ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: And in terms of the 4% to 8%, we are still confident of returning to that, as I said earlier. We talked about the building blocks to that. The one thing I didn't mention, I guess, is price. We have been quite conservative on price in the last couple of years, as you'd probably expect during the CMA process. But we absolutely believe that clients will pay for high-quality care. And we continue to invest in improving our practices and investing in our teams to provide that continued great care to our clients and their animals. So with some pricing, the return to consumer confidence, the investment in quality and also making sure that we service the increased demand that will come from that COVID cohort of puppies and kittens, there are a number of building blocks you can see that will hopefully get us back to that medium-term ambition.</td><td>**CEO & Director:** 4%ì—ì„œ 8% ë²”ìœ„ë¡œì˜ ë³µê·€ì— ëŒ€í•´ì„œëŠ” ì•ì„œ ë§ì”€ë“œë¦° ëŒ€ë¡œ ì—¬ì „íˆ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¥¼ ìœ„í•œ êµ¬ì„± ìš”ì†Œë“¤ì— ëŒ€í•´ì„œë„ ë§ì”€ë“œë ¸ê³ ìš”. ì œê°€ ì–¸ê¸‰í•˜ì§€ ì•Šì€ í•œ ê°€ì§€ê°€ ìˆë‹¤ë©´ ë°”ë¡œ ê°€ê²©ì…ë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë…„ê°„ CMA ì ˆì°¨ë¥¼ ì§„í–‰í•˜ëŠ” ë™ì•ˆ ê°€ê²© ì±…ì •ì— ìˆì–´ì„œëŠ” ìƒë‹¹íˆ ë³´ìˆ˜ì ì¸ ì ‘ê·¼ì„ í•´ì™”ìŠµë‹ˆë‹¤. ì´ëŠ” ì—¬ëŸ¬ë¶„ë„ ì˜ˆìƒí•˜ì…¨ì„ ê²ƒì…ë‹ˆë‹¤.<br><br>í•˜ì§€ë§Œ ê³ ê°ë“¤ì´ ê³ í’ˆì§ˆ ì¼€ì–´ì— ëŒ€í•´ì„œëŠ” ê¸°êº¼ì´ ë¹„ìš©ì„ ì§€ë¶ˆí•  ê²ƒì´ë¼ê³  í™•ì‹ í•©ë‹ˆë‹¤. ì €í¬ëŠ” ê³ ê°ê³¼ ë°˜ë ¤ë™ë¬¼ë“¤ì—ê²Œ ì§€ì†ì ìœ¼ë¡œ í›Œë¥­í•œ ì¼€ì–´ë¥¼ ì œê³µí•˜ê¸° ìœ„í•´ ë³‘ì› ì‹œì„¤ ê°œì„ ê³¼ íŒ€ íˆ¬ìë¥¼ ê³„ì†í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê°€ê²© ì¡°ì •ê³¼ ì†Œë¹„ì ì‹ ë¢° íšŒë³µ, í’ˆì§ˆì— ëŒ€í•œ íˆ¬ì, ê·¸ë¦¬ê³  ì½”ë¡œë‚˜19 ì‹œê¸°ì— ì…ì–‘ëœ ê°•ì•„ì§€ì™€ ê³ ì–‘ì´ë“¤ë¡œ ì¸í•´ ì¦ê°€í•  ìˆ˜ìš”ì— ëŒ€í•œ ì„œë¹„ìŠ¤ ì¤€ë¹„ ë“± ì—¬ëŸ¬ êµ¬ì„± ìš”ì†Œë“¤ì„ í†µí•´ ì¤‘ê¸° ëª©í‘œë¡œ ë‹¤ì‹œ ëŒì•„ê°ˆ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Charles Weston: RBC Capital Markets, Research Division And just last question from me, if I can. In the prepared remarks on the video, you said that there was an expectation that there may be U.K. M&A opportunities opening up at the end of the CMA investigation. Have you sort of had conversations with potential vendors already? Is that -- do you envisage that being more sort of trading between the groups or more of a sort of independence, perhaps selling up with perhaps additional pressure from CMA?</td><td>**Charles Weston:** ì¤€ë¹„ëœ ë°œì–¸ ì˜ìƒì—ì„œ CMA ì¡°ì‚¬ê°€ ëë‚˜ë©´ ì˜êµ­ M&A ê¸°íšŒê°€ ì—´ë¦´ ê²ƒìœ¼ë¡œ ì˜ˆìƒëœë‹¤ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ì´ë¯¸ ì ì¬ì  ë§¤ë„ìë“¤ê³¼ ëŒ€í™”ë¥¼ ë‚˜ëˆ„ì…¨ë‚˜ìš”? ê·¸ë£¹ ê°„ ê±°ë˜ê°€ ë” ë§ì„ ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€, ì•„ë‹ˆë©´ CMAì˜ ì¶”ê°€ì ì¸ ì••ë°•ìœ¼ë¡œ ë…ë¦½ì—…ì²´ë“¤ì´ ë§¤ê°í•˜ëŠ” í˜•íƒœê°€ ë” ë§ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. I think probably the latter in that. I suspect there are a number of independent practice owners that may have considered selling their practice and have possibly been frustrated over the last couple of years because we know Linnaeus bought a small group in the Rutland area, but there haven't been many transactions that have happened. We're all eagerly waiting the CMA findings, and they will apply across the entire sector, not just for the corporate groups. And therefore, we do expect some vendors will want to approach corporate groups and look to sell their practices post CMA process. We will continue to be selective. We would hope multiples have come down from the peak a few years ago. But we absolutely believe there are U.K. acquisition opportunities. And we have less than a 9% market share. So there are plenty of white spaces in the U.K. where we don't currently own practices or we own very little. And selective acquisitions can certainly augment the practices that we already own. Thanks, Charles. Sahill?</td><td>**CEO & Director:** ë„¤, ì•„ë§ˆ í›„ìì¼ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë…ë¦½ ë³‘ì› ì†Œìœ ì£¼ë“¤ ì¤‘ ìƒë‹¹ìˆ˜ê°€ ìì‹ ì˜ ë³‘ì› ë§¤ê°ì„ ê³ ë ¤í–ˆì§€ë§Œ, ì§€ë‚œ ëª‡ ë…„ê°„ ì¢Œì ˆê°ì„ ëŠê¼ˆì„ ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¦¬ë‚˜ì—ìš°ìŠ¤(Linnaeus)ê°€ ëŸ¬í‹€ëœë“œ ì§€ì—­ì˜ ì†Œê·œëª¨ ê·¸ë£¹ì„ ì¸ìˆ˜í•œ ê²ƒ ì™¸ì—ëŠ” ì‹¤ì œë¡œ ì„±ì‚¬ëœ ê±°ë˜ê°€ ë§ì§€ ì•Šì•˜ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.<br><br>ì €í¬ëŠ” ëª¨ë‘ CMA ì¡°ì‚¬ ê²°ê³¼ë¥¼ ê°„ì ˆíˆ ê¸°ë‹¤ë¦¬ê³  ìˆìœ¼ë©°, ì´ ê²°ê³¼ëŠ” ê¸°ì—… ê·¸ë£¹ë¿ë§Œ ì•„ë‹ˆë¼ ì „ì²´ ì—…ê³„ì— ì ìš©ë  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì¼ë¶€ ë§¤ë„ìë“¤ì´ CMA ì ˆì°¨ ì™„ë£Œ í›„ ê¸°ì—… ê·¸ë£¹ì— ì ‘ê·¼í•˜ì—¬ ë³‘ì› ë§¤ê°ì„ ì¶”ì§„í•˜ê³ ì í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.<br><br>ì €í¬ëŠ” ê³„ì†í•´ì„œ ì„ ë³„ì ìœ¼ë¡œ ì ‘ê·¼í•  ê²ƒì…ë‹ˆë‹¤. ëª‡ ë…„ ì „ ìµœê³ ì  ëŒ€ë¹„ ë©€í‹°í”Œ(multiples)ì´ í•˜ë½í–ˆê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì˜êµ­ ë‚´ ì¸ìˆ˜ ê¸°íšŒê°€ ë¶„ëª…íˆ ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” 9% ë¯¸ë§Œì˜ ì‹œì¥ ì ìœ ìœ¨ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì˜êµ­ì—ëŠ” ì €í¬ê°€ í˜„ì¬ ì§„ë£Œì†Œë¥¼ ì†Œìœ í•˜ì§€ ì•Šê±°ë‚˜ ë§¤ìš° ì ê²Œ ì†Œìœ í•œ ê³µë°± ì§€ì—­ì´ ì¶©ë¶„íˆ ë§ìŠµë‹ˆë‹¤. ì„ ë³„ì ì¸ ì¸ìˆ˜ë¥¼ í†µí•´ ì €í¬ê°€ ì´ë¯¸ ì†Œìœ í•œ ì§„ë£Œì†Œë“¤ì„ í™•ì‹¤íˆ ë³´ê°•í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê³ ë§™ìŠµë‹ˆë‹¤, Charles. Sahill?</td></tr>
<tr><td>Sahill Shan: Singer Capital Markets Securities Limited, Research Division Sahill from Singer Capital. Charles actually just got one of my questions in there. But just sort of building on the UK acquisition, how should we be thinking about your view on capital deployment going forward over the next few years or so? Because clearly, Australia has got good momentum at the moment. The multiples are attractive. Just sort of help me get a sense of that. Secondly, where are we in terms of greenfields in the U.K. and the ones you opened a few years ago? Just an update on that would be really helpful and plans going forward once we get clarity on the CMA. And probably one for Robin. Given last year, there was a lot of cost headwinds and you did really well in terms of improving margins, do you have a sense of what kind of like-for-likes you'll need this year to offset any cost inflation that you're anticipating in the current financial year?</td><td>**Sahill Shan:** Singer Capitalì˜ Sahillì…ë‹ˆë‹¤. Charlesê°€ ë°©ê¸ˆ ì œ ì§ˆë¬¸ ì¤‘ í•˜ë‚˜ë¥¼ ë‹µë³€í•´ ì£¼ì…¨ëŠ”ë°ìš”. ì˜êµ­ ì¸ìˆ˜ê±´ê³¼ ê´€ë ¨í•´ì„œ ì¶”ê°€ë¡œ ì§ˆë¬¸ë“œë¦¬ë©´, í–¥í›„ ëª‡ ë…„ê°„ ìë³¸ ë°°ì¹˜ì— ëŒ€í•œ ì „ëµì„ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”? í˜„ì¬ í˜¸ì£¼ ì‹œì¥ì´ ì¢‹ì€ ëª¨ë©˜í…€ì„ ë³´ì´ê³  ìˆê³  ë°¸ë¥˜ì—ì´ì…˜ ë°°ìˆ˜ë„ ë§¤ë ¥ì ì¸ ìƒí™©ì´ë‹ˆê¹Œìš”. ì´ ë¶€ë¶„ì— ëŒ€í•´ ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ì„¤ëª…í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ë¡œ, ì˜êµ­ì˜ ê·¸ë¦°í•„ë“œ ì‚¬ì—…ì€ ì–´ë–¤ ìƒí™©ì¸ê°€ìš”? ëª‡ ë…„ ì „ì— ì˜¤í”ˆí•œ ë§¤ì¥ë“¤ ë§ì…ë‹ˆë‹¤. í˜„ì¬ ì§„í–‰ ìƒí™©ê³¼ CMA(ê²½ìŸì‹œì¥ì²­) ìŠ¹ì¸ì´ ë‚˜ì˜¨ í›„ì˜ í–¥í›„ ê³„íšì— ëŒ€í•´ ì—…ë°ì´íŠ¸í•´ ì£¼ì‹œë©´ ì •ë§ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì•„ë§ˆ Robinì—ê²Œ ë“œë¦´ ì§ˆë¬¸ì´ í•˜ë‚˜ ìˆìŠµë‹ˆë‹¤. ì‘ë…„ì— ë§ì€ ë¹„ìš© ìƒìŠ¹ ì••ë°•ì´ ìˆì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  ë§ˆì§„ ê°œì„ ì—ì„œ ì •ë§ ì¢‹ì€ ì„±ê³¼ë¥¼ ê±°ë‘ì…¨ëŠ”ë°, ì˜¬ íšŒê³„ì—°ë„ì— ì˜ˆìƒë˜ëŠ” ë¹„ìš© ì¸í”Œë ˆì´ì…˜ì„ ìƒì‡„í•˜ê¸° ìœ„í•´ ì–´ëŠ ì •ë„ì˜ ë™ì¼ë§¤ì¥ë§¤ì¶œ ì„±ì¥ë¥ ì´ í•„ìš”í• ì§€ ê°ì´ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>CEO & Director: Do you want to start with that one? And I'll pick up the capital deployment.</td><td>**CEO & Director:** ê·¸ ë¶€ë¶„ë¶€í„° ì‹œì‘í•˜ì‹œê² ì–´ìš”? ê·¸ëŸ¬ë©´ ì œê°€ ìë³¸ ë°°ë¶„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CFO & Director: Yes. So as you rightly say, we faced in some national wage increases last year, some national insurance contribution increases. We said the annualized impact of that was between GBP 11 million to GBP 12 million. It started from April '25, so there's some annualization of those costs. Against that, we have been looking at our cost base. I suppose the areas that we've been looking at to kind of help drive, there's some efficiency savings in terms of headcount and we've delivered some of that already. We delivered sufficient to kind of offset those costs. There are also some purchasing synergies. We every day look at buying of drugs and make sure that we have the most optimum net-net price. But we actually think there's an opportunity right now for us to drive that harder, and I think that will help offset. And then we've locked in some favorable kind of utility cost savings. We forward buy our gas and electricity. So those three will offset, I believe, most of the cost inflation. We've not shared kind of a like-for-like guidance number, but I think the kind of the market consensus revenue and the like-for-likes will be sufficient to offset kind of cost inflation, plus those activities.</td><td>**CFO & Director:** ë„¤, ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì‘ë…„ì— ì¼ë¶€ êµ­ê°€ì  ì„ê¸ˆ ì¸ìƒê³¼ êµ­ë¯¼ë³´í—˜ ê¸°ì—¬ê¸ˆ ì¸ìƒì— ì§ë©´í–ˆìŠµë‹ˆë‹¤. ì´ì— ë”°ë¥¸ ì—°ê°„ ì˜í–¥ì€ 1,100ë§Œ íŒŒìš´ë“œì—ì„œ 1,200ë§Œ íŒŒìš´ë“œ ì‚¬ì´ë¼ê³  ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ì´ëŠ” 25ë…„ 4ì›”ë¶€í„° ì‹œì‘ë˜ì—ˆê¸° ë•Œë¬¸ì— í•´ë‹¹ ë¹„ìš©ë“¤ì˜ ì¼ë¶€ ì—°ê°„í™”ê°€ ìˆìŠµë‹ˆë‹¤.<br><br>ì´ì— ëŒ€ì‘í•˜ì—¬ ì €í¬ëŠ” ë¹„ìš© ê¸°ë°˜ì„ ê²€í† í•´ì™”ìŠµë‹ˆë‹¤. íš¨ìœ¨ì„± ê°œì„ ì„ ì¶”ì§„í•˜ê¸° ìœ„í•´ ì‚´í´ë³¸ ì˜ì—­ë“¤ì„ ë§ì”€ë“œë¦¬ë©´, ì¸ë ¥ ì¸¡ë©´ì—ì„œ ì¼ë¶€ íš¨ìœ¨ì„± ì ˆê°ì´ ìˆì—ˆê³  ì´ë¯¸ ê·¸ ì¼ë¶€ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í•´ë‹¹ ë¹„ìš©ë“¤ì„ ìƒì‡„í•  ìˆ˜ ìˆì„ ë§Œí¼ ì¶©ë¶„íˆ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë˜í•œ êµ¬ë§¤ ì‹œë„ˆì§€ë„ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë§¤ì¼ ì˜ì•½í’ˆ êµ¬ë§¤ë¥¼ ê²€í† í•˜ì—¬ ìµœì ì˜ ìˆœê°€ê²©ì„ í™•ë³´í•˜ë„ë¡ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‹¤ì œë¡œ ì§€ê¸ˆ ì €í¬ê°€ ë” ê°•ë ¥í•˜ê²Œ ì¶”ì§„í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆë‹¤ê³  ìƒê°í•˜ê³ , ì´ê²ƒì´ ìƒì‡„ íš¨ê³¼ë¥¼ ê°€ì ¸ë‹¤ì¤„ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìœ í‹¸ë¦¬í‹° ë¹„ìš© ì ˆê°ì—ì„œ ìœ ë¦¬í•œ ì¡°ê±´ë“¤ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê°€ìŠ¤ì™€ ì „ë ¥ì„ ì„ êµ¬ë§¤í•˜ê³  ìˆê±°ë“ ìš”. ì´ ì„¸ ê°€ì§€ ìš”ì†Œê°€ ëŒ€ë¶€ë¶„ì˜ ë¹„ìš© ì¸í”Œë ˆì´ì…˜ì„ ìƒì‡„í•  ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤. ë™ì¼ì í¬ë§¤ì¶œ(like-for-like) ê°€ì´ë˜ìŠ¤ ìˆ˜ì¹˜ëŠ” ë”°ë¡œ ê³µìœ í•˜ì§€ ì•Šì•˜ì§€ë§Œ, ì‹œì¥ ì»¨ì„¼ì„œìŠ¤ ë§¤ì¶œê³¼ ë™ì¼ì í¬ë§¤ì¶œì´ ë¹„ìš© ì¸í”Œë ˆì´ì…˜ê³¼ ì´ëŸ¬í•œ í™œë™ë“¤ì„ ì¶©ë¶„íˆ ìƒì‡„í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: And then in terms of capital deployment, Sahill, we are in a good position, I guess, in our leverage reduced during the year. And we finished the year at 1.18x. So we have capital to deploy and we will continue to adopt our selective and disciplined investment criteria. In terms of those investments, we absolutely believe there's an opportunity too for further accretive acquisitions in Australia and, as I said, returning to U.K. acquisitions hopefully in this financial year. But we will continue to be selective in terms of the practices we acquire. We're also committed to improving our existing facilities in the U.K., and that's both the practices themselves and the space both from a client perspective but also for our teams, and also investing in high-quality equipment because obviously that allows us to provide that great care to our clients and their animals. So we will -- the three of us sign off on all investments, and we will continue to adopt that disciplined approach. But we do see options ahead in terms of further investment for growth and we're seeing good returns from that investment at the moment. In terms of greenfields, we have opened a few greenfields in the last few years. And that, I guess, if we don't see an acquisition opportunity in a certain area we want to expand, that can be helpful. I suspect in the U.K., our focus will be more on acquisitions rather than further greenfield sites. That's not to say there won't be any. But I guess, we do feel acquisitions will be back on the table this year. Any questions from the call?</td><td>**CEO & Director:** ìë³¸ ë°°ì¹˜ ì¸¡ë©´ì—ì„œ ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ë ˆë²„ë¦¬ì§€ê°€ ê°ì†Œí–ˆê³  ì—°ë§ ê¸°ì¤€ìœ¼ë¡œ 1.18ë°°ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë°°ì¹˜í•  ìë³¸ì´ ìˆìœ¼ë©°, ì•ìœ¼ë¡œë„ ì„ ë³„ì ì´ê³  ê·œìœ¨ ìˆëŠ” íˆ¬ì ê¸°ì¤€ì„ ê³„ì† ì ìš©í•  ê²ƒì…ë‹ˆë‹¤.<br><br>ì´ëŸ¬í•œ íˆ¬ìì™€ ê´€ë ¨í•´ì„œëŠ”, í˜¸ì£¼ì—ì„œ ì¶”ê°€ì ì¸ ê°€ì¹˜ ì°½ì¶œí˜• ì¸ìˆ˜ ê¸°íšŒê°€ ë¶„ëª…íˆ ìˆë‹¤ê³  í™•ì‹ í•˜ë©°, ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ì´ë²ˆ íšŒê³„ì—°ë„ì—ëŠ” ì˜êµ­ ì¸ìˆ˜ë¡œë„ ë³µê·€í•˜ê¸°ë¥¼ í¬ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì¸ìˆ˜í•˜ëŠ” ì‚¬ì—…ì²´ë“¤ì— ëŒ€í•´ì„œëŠ” ê³„ì†í•´ì„œ ì„ ë³„ì ì¸ ì ‘ê·¼ì„ ìœ ì§€í•  ê²ƒì…ë‹ˆë‹¤. ì˜êµ­ ë‚´ ê¸°ì¡´ ì‹œì„¤ ê°œì„ ì—ë„ ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì§„ë£Œì†Œ ìì²´ì™€ ê³µê°„ ëª¨ë‘ë¥¼ í¬í•¨í•˜ëŠ”ë°, ê³ ê° ê´€ì ì—ì„œë¿ë§Œ ì•„ë‹ˆë¼ ì €í¬ íŒ€ì„ ìœ„í•´ì„œë„ ê·¸ë ‡ê³ , ê³ í’ˆì§ˆ ì¥ë¹„ì— ëŒ€í•œ íˆ¬ìë„ í¬í•¨ë©ë‹ˆë‹¤. ì´ëŸ° íˆ¬ìê°€ ê³ ê°ê³¼ ê·¸ë“¤ì˜ ë°˜ë ¤ë™ë¬¼ì—ê²Œ í›Œë¥­í•œ ì§„ë£Œë¥¼ ì œê³µí•  ìˆ˜ ìˆê²Œ í•´ì£¼ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <br><br>ì €í¬ ì„¸ ëª…ì´ ëª¨ë“  íˆ¬ìì— ëŒ€í•´ ìŠ¹ì¸í•˜ë©°, ì•ìœ¼ë¡œë„ ì´ëŸ° ì²´ê³„ì ì¸ ì ‘ê·¼ ë°©ì‹ì„ ê³„ì† ìœ ì§€í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì„±ì¥ì„ ìœ„í•œ ì¶”ê°€ íˆ¬ì ì˜µì…˜ë“¤ì´ ìˆë‹¤ê³  ë³´ê³  ìˆìœ¼ë©°, í˜„ì¬ ê·¸ëŸ° íˆ¬ìë¡œë¶€í„° ì¢‹ì€ ìˆ˜ìµì„ ê±°ë‘ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì‹ ê·œ ê°œë°œ(greenfield) ê´€ë ¨í•´ì„œëŠ” ì§€ë‚œ ëª‡ ë…„ê°„ ëª‡ ê³³ì„ ìƒˆë¡œ ì—´ì—ˆìŠµë‹ˆë‹¤. í™•ì¥í•˜ê³ ì í•˜ëŠ” íŠ¹ì • ì§€ì—­ì—ì„œ ì¸ìˆ˜ ê¸°íšŒë¥¼ ì°¾ì§€ ëª»í•  ê²½ìš°, ì´ëŸ° ë°©ì‹ì´ ë„ì›€ì´ ë  ìˆ˜ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì˜êµ­ì—ì„œëŠ” ì¶”ê°€ì ì¸ ì‹ ê·œ ë¶€ì§€ ê°œë°œë³´ë‹¤ëŠ” ì¸ìˆ˜í•©ë³‘ì— ë” ì§‘ì¤‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë¬¼ë¡  ì‹ ê·œ ê°œë°œì´ ì „í˜€ ì—†ë‹¤ëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. í•˜ì§€ë§Œ ì˜¬í•´ëŠ” ì¸ìˆ˜í•©ë³‘ì´ ë‹¤ì‹œ í…Œì´ë¸” ìœ„ì— ì˜¬ë¼ì˜¬ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì „í™” ì°¸ì—¬ìë¶„ë“¤ ì¤‘ì— ì§ˆë¬¸ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>Operator: So there's no questions from the calls but we do have one from the webcast from Roland French from Penman Securities. How are you incorporating AI or machine learning into the practices and your broader processes? And is there an opportunity here?</td><td>**Operator:** ì „í™”ë¡œ ë“¤ì–´ì˜¨ ì§ˆë¬¸ì€ ì—†ì§€ë§Œ ì›¹ìºìŠ¤íŠ¸ë¥¼ í†µí•´ Penman Securitiesì˜ Roland Frenchë¡œë¶€í„° ì§ˆë¬¸ì´ í•˜ë‚˜ ë“¤ì–´ì™”ìŠµë‹ˆë‹¤. AIë‚˜ ë¨¸ì‹ ëŸ¬ë‹ì„ ì—…ë¬´ ê´€í–‰ê³¼ ì „ë°˜ì ì¸ í”„ë¡œì„¸ìŠ¤ì— ì–´ë–»ê²Œ ë„ì…í•˜ê³  ê³„ì‹ ê°€ìš”? ê·¸ë¦¬ê³  ì—¬ê¸°ì— ê¸°íšŒê°€ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>CEO & Director: Absolutely, there is. And I'll hand over to Paul, who's actually using some of the AI at the present.</td><td>**CEO & Director:** ë¬¼ë¡ ì…ë‹ˆë‹¤. í˜„ì¬ ì‹¤ì œë¡œ AIë¥¼ í™œìš©í•˜ê³  ìˆëŠ” Paulì—ê²Œ ë„˜ê²¨ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Veterinary Officer: Yes. I think we need to probably separate out the AI and machine learning, which is a separate component. We certainly at the moment don't use machine learning from a clinical diagnostics perspective, and that's importantly from my perspective as Chief Veterinary Officer that, at the moment, we don't have sufficient evidence to be secure in the way that, that's functioning. So we're exploring it but not something that we're engaging fully with. What we are using AI with is support in the consulting room, again, to build in efficiencies. So we have a trial at the moment with a scribing AI function, which will record the consultation so that the vet has to make no notes at all, can fully engage with the owner. And it will then structure the clinical notes in the same format every single time. And it can then also automatically create a note for the owner take away, so what would have, within the profession, be termed at lay person's interpretation of the clinical notes. So it actually really builds in not just efficiencies in there but enables really great clinical record taking, which can be a challenge in the time frame that we have, but it also allows our colleagues to engage directly with owners and not have to worry about writing those notes at the same time. So that's the key element of AI that's in practices that we are using at the moment.</td><td>**Chief Veterinary Officer:** ë„¤, AIì™€ ë¨¸ì‹ ëŸ¬ë‹ì„ ë¶„ë¦¬í•´ì„œ ìƒê°í•´ì•¼ í•  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì´ëŠ” ë³„ê°œì˜ êµ¬ì„± ìš”ì†Œì…ë‹ˆë‹¤. í˜„ì¬ ì €í¬ëŠ” ì„ìƒ ì§„ë‹¨ ê´€ì ì—ì„œ ë¨¸ì‹ ëŸ¬ë‹ì„ ì‚¬ìš©í•˜ì§€ ì•Šê³  ìˆìœ¼ë©°, ìµœê³ ìˆ˜ì˜ì‚¬ë¡œì„œ ì œ ê´€ì ì—ì„œëŠ” í˜„ì¬ë¡œì„œëŠ” ê·¸ ê¸°ëŠ¥ì´ ì•ˆì „í•˜ê²Œ ì‘ë™í•œë‹¤ëŠ” ì¶©ë¶„í•œ ì¦ê±°ê°€ ì—†ë‹¤ëŠ” ì ì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ë”°ë¼ì„œ íƒìƒ‰ì€ í•˜ê³  ìˆì§€ë§Œ ì™„ì „íˆ ë„ì…í•˜ì§€ëŠ” ì•Šê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì €í¬ê°€ AIë¥¼ í™œìš©í•˜ê³  ìˆëŠ” ë¶„ì•¼ëŠ” ì§„ë£Œì‹¤ì—ì„œì˜ ì§€ì›ì„ í†µí•´ íš¨ìœ¨ì„±ì„ ë†’ì´ëŠ” ê²ƒì…ë‹ˆë‹¤. í˜„ì¬ ìŠ¤í¬ë¼ì´ë¹™ AI ê¸°ëŠ¥ìœ¼ë¡œ ì‹œë²” ìš´ì˜ì„ í•˜ê³  ìˆëŠ”ë°, ì´ëŠ” ì§„ë£Œ ìƒë‹´ì„ ë…¹ìŒí•´ì„œ ìˆ˜ì˜ì‚¬ê°€ ì „í˜€ ë©”ëª¨ë¥¼ í•  í•„ìš” ì—†ì´ ë³´í˜¸ìì™€ ì™„ì „íˆ ì§‘ì¤‘í•´ì„œ ì†Œí†µí•  ìˆ˜ ìˆë„ë¡ í•´ì¤ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§¤ë²ˆ ë™ì¼í•œ í˜•ì‹ìœ¼ë¡œ ì„ìƒ ë…¸íŠ¸ë¥¼ êµ¬ì¡°í™”í•©ë‹ˆë‹¤. ë˜í•œ ì†Œìœ ìê°€ ê°€ì ¸ê°ˆ ìˆ˜ ìˆëŠ” ë…¸íŠ¸ë¥¼ ìë™ìœ¼ë¡œ ìƒì„±í•  ìˆ˜ ìˆëŠ”ë°, ì´ëŠ” ì—…ê³„ì—ì„œ ì„ìƒ ë…¸íŠ¸ì˜ ì¼ë°˜ì¸ í•´ì„ì´ë¼ê³  ë¶€ë¥´ëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ê¸°ìˆ ì€ ë‹¨ìˆœíˆ íš¨ìœ¨ì„±ì„ ë†’ì´ëŠ” ê²ƒë¿ë§Œ ì•„ë‹ˆë¼ ìš°ìˆ˜í•œ ì„ìƒ ê¸°ë¡ ì‘ì„±ì„ ê°€ëŠ¥í•˜ê²Œ í•©ë‹ˆë‹¤. ì´ëŠ” ì œí•œëœ ì‹œê°„ ë‚´ì—ì„œ ì–´ë ¤ìš´ ê³¼ì œê°€ ë  ìˆ˜ ìˆì§€ë§Œ, ë™ì‹œì— ìš°ë¦¬ ë™ë£Œë“¤ì´ ë…¸íŠ¸ ì‘ì„±ì— ëŒ€í•œ ê±±ì • ì—†ì´ ì†Œìœ ìë“¤ê³¼ ì§ì ‘ ì†Œí†µí•  ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤. ì´ê²ƒì´ í˜„ì¬ ìš°ë¦¬ê°€ ì§„ë£Œì†Œì—ì„œ ì‚¬ìš©í•˜ê³  ìˆëŠ” AIì˜ í•µì‹¬ ìš”ì†Œì…ë‹ˆë‹¤.</td></tr>
<tr><td>CFO & Director: It's just worth adding, we also already use AI in terms of those processing of invoices through AP. That's something we've been using for some time already.</td><td>**CFO & Director:** ë˜í•œ ë§ë¶™ì´ìë©´, ì €í¬ëŠ” ì´ë¯¸ ë§¤ì…ì±„ë¬´(AP) ì²˜ë¦¬ë¥¼ í†µí•œ ì†¡ì¥ ì²˜ë¦¬ì—ì„œ AIë¥¼ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì´ë¯¸ ìƒë‹¹ ê¸°ê°„ ì‚¬ìš©í•´ì˜¨ ê¸°ìˆ ì…ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Brilliant. Any other questions?</td><td>**CEO & Director:** í›Œë¥­í•©ë‹ˆë‹¤. ë‹¤ë¥¸ ì§ˆë¬¸ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>Operator: That's all the questions from the webcast. Over to you, Richard, for closing remarks.</td><td>**Operator:** ì›¹ìºìŠ¤íŠ¸ë¥¼ í†µí•œ ì§ˆë¬¸ì€ ì´ìƒìœ¼ë¡œ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ë§ˆë¬´ë¦¬ ë§ì”€ì„ ìœ„í•´ ë¦¬ì²˜ë“œë‹˜ê»˜ ë„˜ê²¨ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Director: Yes. Thank you. So first of all, thank you all for joining this presentation this morning, and thank you for your continued support. I'd like to close by thanking our fantastic team of colleagues because these results are all due to their contribution and significant focus on providing great care to our clients and their animals, and we really appreciate all of their hard work. And I look forward to sharing further success with you all in the coming months and years. Thank you.</td><td>**CEO & Director:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤. ë¨¼ì € ì˜¤ëŠ˜ ì•„ì¹¨ ì´ ë°œí‘œì— ì°¸ì„í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦¬ë©°, ì§€ì†ì ì¸ ì§€ì›ì—ë„ ê¹Šì´ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì €í¬ì˜ í›Œë¥­í•œ ë™ë£Œë“¤ì—ê²Œ ê°ì‚¬ì˜ ë§ì”€ì„ ì „í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ê³¼ëŠ” ëª¨ë‘ ê·¸ë“¤ì˜ ê¸°ì—¬ì™€ ê³ ê° ë° ë°˜ë ¤ë™ë¬¼ë“¤ì—ê²Œ ìµœê³ ì˜ ì¼€ì–´ë¥¼ ì œê³µí•˜ë ¤ëŠ” í—Œì‹ ì ì¸ ë…¸ë ¥ ë•ë¶„ì…ë‹ˆë‹¤. ê·¸ë“¤ì˜ ëª¨ë“  ë…¸ê³ ì— ì§„ì‹¬ìœ¼ë¡œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì•ìœ¼ë¡œ ëª‡ ê°œì›”, ëª‡ ë…„ê°„ ì—¬ëŸ¬ë¶„ê³¼ ë” ë§ì€ ì„±ê³µì„ ê³µìœ í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here are the key points from the earnings call transcript in Korean:<br><br>â€¢ í˜¸ì£¼ ì‚¬ì—… í˜„í™©:<br>- í˜¸ì£¼ ì‹œì¥ì˜ 15-20% ì ìœ ìœ¨ ë³´ìœ  (ì˜êµ­ì˜ 60% ëŒ€ë¹„ ë‚®ì€ ìˆ˜ì¤€)<br>- ìµœê·¼ ë¶„ê¸°ì— 2ê±´ì˜ ì¸ìˆ˜ ì™„ë£Œ (ì•½ 2,300ë§Œ íŒŒìš´ë“œ íˆ¬ì)<br>- ë†’ì€ ìˆ˜ìµì„±ê³¼ ê°•í•œ íŒŒì´í”„ë¼ì¸ ë³´ìœ  ì¤‘<br><br>â€¢ ì¬ë¬´ ì‹¤ì  ë° ì „ë§:<br>- 4ë¶„ê¸° 2-3% ìˆ˜ì¤€ì˜ ìœ ê¸°ì  ì„±ì¥ ë‹¬ì„±<br>- ì¤‘ê¸° ëª©í‘œì¸ 4-8% ì„±ì¥ë¥  ë‹¬ì„±ì— ëŒ€í•œ ìì‹ ê° í‘œëª…<br>- ë ˆë²„ë¦¬ì§€ ë¹„ìœ¨ 1.18xë¡œ ê±´ì „í•œ ì¬ë¬´êµ¬ì¡° ìœ ì§€<br><br>â€¢ ì„±ì¥ ì „ëµ:<br>- ì˜êµ­ CMA ì¡°ì‚¬ ì¢…ë£Œ í›„ M&A ê¸°íšŒ í™•ëŒ€ ì˜ˆìƒ<br>- í˜¸ì£¼ì—ì„œ ì„ ë³„ì  ì¸ìˆ˜ ì „ëµ ì§€ì†<br>- AI ê¸°ìˆ  ë„ì…ì„ í†µí•œ ìš´ì˜ íš¨ìœ¨í™” ì¶”ì§„ ì¤‘<br><br>â€¢ ë¦¬ìŠ¤í¬ ìš”ì¸:<br>- ì˜êµ­ ì†Œë¹„ì ì‹ ë¢°ë„ íšŒë³µ í•„ìš”ì„±<br>- ì¸ë ¥ ìˆ˜ê¸‰ ë¬¸ì œëŠ” ê°œì„  ì¤‘ì´ë‚˜ ì—¬ì „íˆ ê³¼ì œë¡œ ë‚¨ì•„ìˆìŒ<br>- ì˜¨ë¼ì¸ ì‚¬ì—…ì—ì„œì˜ í”„ë¦¬ë¯¸ì—„ ì œí’ˆ ìˆ˜ìš” ê°ì†Œ<br><br>â€¢ ê²½ì˜ì§„ í†¤:<br>ì „ë°˜ì ìœ¼ë¡œ ìì‹ ê° ìˆê³  ê¸ì •ì ì¸ í†¤ì„ ìœ ì§€í•˜ë©°, íŠ¹íˆ í˜¸ì£¼ ì‚¬ì—… ì„±ê³¼ì™€ í–¥í›„ ì„±ì¥ ê¸°íšŒì— ëŒ€í•´ ë‚™ê´€ì ì¸ ì…ì¥ì„ ë³´ì„</p>
    <hr style="margin:50px 0;">
    
</body></html>